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You can be anything you want to be 
Just turn yourself into anything  
you think that you could ever be 
 
Queen, Innuendo 
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Introduction 
 
1. Alzheimer’s Disease 
 
Since the turn of the century, a rapidly increase in the life expectancy was driven 
mainly by improvements in sanitation, education and housing. Nowadays, this 
trend continues to rise resulting in an increased probability of developing an age-
associated disease. Indeed, deaths due to dementias are more than doubled 
between 2000 and 2015 for people at the age of 85 and older [1]. Alzheimer’s 
Disease (AD) contributes to 60-70% of these cases. Given the social, economical 
and medical impact of the disease, there is an urgent need to develop an effective 
therapy. Indeed, despite the constant ongoing studies, no new treatments have 
been approved for Alzheimer’s disease since 2003 [2]. The drugs currently in use 
to treat AD such as the cholinesterase inhibitors (donepezil, galantamine, 
rivastigmine) [3] and the N-methyl-D-aspartate receptors antagonist memantine , 
[4] are palliative rather than curative, merely providing symptomatic relief but 
not altering the course of the disease, which is still incurable.  
 
Alzheimer: Where are you? 
Auguste D.: Here and everywhere. Here and now. You don’t mind. 
 
In 1906, at the annual meeting of South-West German psychiatrists, a young 
doctor presented his results concerning a patient who suffered from an unknown 
brain disorder. The talk entitled “Über eine eigenartige Erkrankung der 
Hirnrinde” (“On a peculiar disease of the cerebral cortex”). On that occasion, Dr. 
Alois Alzheimer described the psychiatric symptoms and the histopathological 
brain changes of Auguste D., the woman who has been the first person diagnosed 
with the condition currently called AD [5], [6].  
The progressive and irreversible brain degeneration typical of AD leads at first to 
memory loss, confusion and difficulty speaking followed by mood and personality 
changes with anxiety and aggressiveness increased over time. More the severity of 
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AD increase more the patient is unable to communicate and to recognize family, 
friends or their living environment. At the later stage of the disease, AD sufferers 
become to be completely dependent on other people (NIH, National Institute of 
Aging, https://www.nia.nih.gov). It is therefore predictable the huge cost requests 
for both health-care and long-term care of AD patients that has been estimated to 
be hundreds of dollars billion worldwide. The lifespan increase and the totally lack 
of a cure has led to a constant growing of the AD cost that will triple in 2030 [7].  
A constant and extensive research is attempting to clarify the pathophysiological 
changes altering the AD brain structure as well as the key players involved in the 
development of the disease for over 20 years. However, the fascinating and 
terrible complexity of AD pathophysiology has not been yet resolved.  
The severe cognitive impairment typical of AD goes along with a cerebral atrophy 
which rate appears to be greater compared to what usually takes place in a healthy 
aged brain [8], [9], [10]. As reviewed by Fox and Scott on Lancet in 2004, the 
annual rate of global brain atrophy in healthy people is 0.2% - 0.5% compared 
with 2 - 3% in AD patients [11]. Not only the rate, but also the pattern of the 
cerebral atrophy is found to be qualitative and quantitative different from normal 
aging. In healthy aged brains, the frontal lobe, in particular the prefrontal cortex, 
is the first area loses volume followed by the temporal lobes [12]. On the contrary, 
the topographic pattern of the cortical atrophy occurring in AD brain correlates 
well with the appearance of the clinical symptoms related to the disease. The brain 
damage firstly occurs in the medial temporal lobe [13], where the hippocampus is 
located and new memories are formed. Several Magnetic Resonance Imaging 
(MRI) studies have reported that the most affected brain regions in AD pathology 
are the hippocampus and the enthorinal cortex, which volumes are smaller 
compared to the healthy condition [9], [10], [14], [15]. Longitudinal MRI scans of 
hippocampal atrophy can track, with the appropriate accuracy and reproducibility 
[16], [17], the progression of the disease from MCI to clinical AD as well as from 
normal ageing to cognitive decline [11]. The atrophy progression continues along a 
temporal-parietal-frontal trajectory causing both cortical thinning and lateral 
ventricles dilatation [18].  
The massive reduction occurring in the AD-affected brain is only the ultimate 
stage of the disease. The severe mental disability is preceded by multiple 
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alterations of the brain homeostasis, which prepare to the onset of both intra- and 
extracellular lesions. The neurofibrillary tangles (NFTs) and the amyloid “senile” 
plaques are reported to be the hallmarks of the disease [19]. NFTs are primarily 
made by masses of paired helical filaments derived from the phosphorylation and 
the subsequent abnormal folding of Tau protein [20], [21], [22], [23], [24], an 
intracellular stabilizer of the microtubule filaments [25]. The tangle-bearing 
neurons show an aberrant axonal transport that may lead to a cascade of events 
resulting in neuronal dysfunction and death [26]; as a result, the cytoplasmic 
NFTs became extra-neuronal “ghost NFTs” [24]. Several studies support a 
stereotypical pattern of regional distribution of NFTs, based on Braak staging 
[13], which fits well with the cortical neurodegeneration occurring in AD-affected 
brains (for reviews [18]). Neurofibrillary changes can be distinguished in six 
stages in which NFT pathology is initially confined to the transenthorinal region 
(transentorhinal stages I and II) then involves the medial temporal lobe (limbic 
stages III and VI) and ultimately the associative cortex (isocortical stages V and 
VI) [27]. 
The abnormal oligomerization and accumulation of the amyloid β peptide (Aβ) 
induces the formation of another histopathological feature of AD, the so-called 
senile plaques [19], [28]. Unlike NFTs, the amyloid plaques are only present 
within the extra-neuronal space and they firstly spread in the associative isocortex 
and subsequently in the allocortex as well as basal ganglia and cerebellum [19]. By 
using the newly developed Positron Emission Tomography (PET) imaging agents 
able to bind tau protein, it has been shown that NFTs better tracks the cognitive 
decline of AD-affected brain [29]. The amyloid plaques thus appear to be weakly 
connected with the progressive cerebral dysfunction and degeneration that occurs 
in AD brains [30]. However, the dominant model of AD pathogenesis has become, 
and still remains, the “amyloid hypothesis” that establish Aβ as the main trigger of 
a cascade of pathological events that occurs in the brain and eventually leads to 
AD [31], [32], [33]. The NFTs formation has been found to be a downstream event 
to amyloid accumulation [33], clarifying the more closely correlation of tau 
pathology with cortex neurodegeneration compared to Aβ spreading. 
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AD is divided into several subtypes depending on: - the presence of familial 
determinants (familial AD, FAD and sporadic AD, SAD) - the patient’s age when 
the symptoms are first exhibited, before the age of 60-65 (early onset AD, EOAD) 
or after the age of 60-65 (late-onset AD, LOAD) [34], [35]. The proportion of the 
genetically based AD cases have widely varied over time, from as low as 10% as 
high as 40% or 50% [36], but generally both EOAD and LOAD have a genetic 
predisposition. Approximately 60% of EOAD cases is familial and 13% are 
inherited in an autosomal dominant manner with at least three generations 
affected [37], [38]. LOAD is the most common form of AD, accounting for more 
than 90% of AD total cases [37], which appears as a very complex disease strongly 
influenced by genetic variants in combination with environmental factors and life 
exposure events [39]. Both LOAD and EOAD are associated to four genes which 
mutations or polymorphism result in the disease. In particular, three forms of 
EOAD have been reported to be associated with several mutations of APP [40], 
[41] presenilin 1 (PSEN1) [42] and presenilin 2 (PSEN2) [43], [44] (for review 
[35]). All these genes encode for proteins that are related to the metabolism of Aβ: 
PSEN1 ([45] and PSEN2 [43], [46] are two protein subunits of the γ-secretase 
enzymatic complex involved in the cleavage of APP, which is the transmembrane 
precursor of Aβ peptide [47]. Regarding LOAD, inheritance of one or two ε4 
alleles of the apolipoprotein E gene (ApoE) is considered the most prevalent risk 
factor for this type of AD so far [48], [49]. ApoE ε4 encodes for the ApoE 
glycoprotein, which is highly expressed in the liver, as well as in the brain in 
particular in microglia and astrocytes. ApoE protein is reported to be involved in 
the transport of cholesterol and other lipids in plasma and the Central Nervous 
System (CNS) by binding to the cell surface apoE receptors and therefore plays a 
role in synaptic maintenance [50]. The allelic variant ApoE ε4 gained several toxic 
functions during the pathological condition of LOAD, these could be summarized 
into the following categories: inhibition of hippocampal neurogenesis [51], altered 
cholesterol transport [52], inverse correlation with dendritic spine density [53], 
altered formation of Aβ due to APP processing changing [54]. 
The original criteria for the diagnosis of AD were established by the National 
Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and 
the Alzheimer’s Disease and Related Disorders Association (ADRDA) workgroup 
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in 1984 [55]. However, by 2009, the NINCDS- ADRDA criteria were revised and 
update by the National Institute on Aging (NIA) and the Alzheimer’s Association 
(AA), in order to incorporate more modern innovation in clinical, imaging and AD 
research. The NIA-AA guideline includes the criteria for all-cause dementia as 
well as core criteria to classify individuals with dementia caused by AD [56], [57]. 
The current terminology discriminates between 1) Probable AD and 2) Possible 
AD; it should be noted that a “definitive” stage of AD is not included into the 
diagnostic criteria. The accuracy of the diagnosis for “probable AD” or “possible 
AD” is generally low; sensitivity has been reported to range from 71% to 88% 
whereas specificity ranged from 44% to 71%, depending on the specific 
histopathologic diagnostic criteria used [58]. Thus the assessment of 
pathophysiologically proved AD dementia can only made at post mortem by 
histopathological and morphological analysis of the cerebral tissue, to identify the 
presence of Aβ containing-senile plaques and a regional distribution of NFTs [27]. 
As mentioned by Guy M. McKhann and colleagues: “AD is fundamentally a 
clinical diagnosis”, which requires a complete clinical evaluation of the patient 
health condition - both mental and physical - to ensure that the core criteria are 
satisfied and the final diagnosis is correct as much as possible. The diagnosis of 
the disease starts with a detailed medical history followed by routine phyisical 
exams. Subsequently, the cognitive status of the patient is evaluated through 
diagnostic tests such as the Mini-mental state exam (MMSE) [59] and the Mini-
cog exam [60]; other tests have also been designed to assess the daily abilities, 
quality of life and mood state of sufferers [61]. Besides the neurological 
examinations, advanced imaging techniques are now used in order to exclude 
other brain disorders and also to monitor the regional areas more vulnerable to 
degeneration. The National Institute for health and Care Excellence (NICE) has 
included in the current guideline (NICE 2017) a combination of several structural 
imaging tests for AD diagnosis such as MRI and the positron emission 
tomography (PET) in addition to the perfusion hexamethylpropyleneamine oxime 
(HMPAO) single-photon emission computed tomography (SPECT) and the F-
fluorodeoxyglucose (FDG) PET. By measuring the glucose uptake of neurons and 
glial cells, a positive scan of FDG-PET is able to suggest AD pathology if the 
pattern is temporoparietal and posterior cingulate [62] discriminating between 
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AD and other subtypes of dementia. Depending on the result of the brain imaging 
analysis, it could be recommended the use of cerebrospinal fluid (CSF) 
biomarkers. Even though the CSF examination is not recommended as routine 
investigation for dementia, the International Working Group and the NIA-AA 
suggest that it may add scientific value to AD diagnosis [57], [63]. However, the 
pathobiological variance typical of AD precludes any biomarker to have a 100% 
diagnostic accuracy; for this reason the combination between AD biomarkers and 
imaging studies may help to make a diagnostic decision [64]. The most widely 
studied CSF biomarkers of AD are Aβ peptide, total Tau (t-Tau) and 
phosphorylated Tau (p-Tau) [65], [66]. These biomarkers, in addition to MRI, 
PET amyloid imaging and FDG-PET, were included in the hypothetical model of 
AD biomarkers proposed by C. R. Jack and colleagues in 2010 [67] and revised in 
2013 [64]. The model is focused on the temporal ordering of amyloid biomarkers, 
identified by CSF Aβ and PET amyloid imaging, and the neurodegeneration 
markers, identified by CSF tau, MRI and FDG-PET, of AD pathology. As described 
by the model, the Aβ deposition is the first abnormality occurring before the onset 
Figure 1.1 - Revised version of the dynamic biomarkers of the AD pathological cascade 
model.   
Aβ deposition is measured by CSF Aβ42 (purple) or PET amyloid imaging (red). Tau 
pathology is measured by CSF total (t-tau) and phosphorylated (p-tau) tau (blue). 
Neurodegeneration is measured by MRI+FDGPET (orange). The green zone corresponds to 
the cognitive response of dementia sufferers with low and high risk boarders . X-axis shows 
the disease progression expressed as time. All biomarkers converge at the top right-hand 
corner of the plot that define the point of maximum abnormality. Image from C.R Jack et al. 
2013. 
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of tau pathology. It is followed by synaptic loss and brain atrophy, which proceed 
the clinical symptoms of the cognitive impairment occurring at the latest stage of 
the disease (Fig.1.1) [64]. In recent years, new AD biomarkers continue to be 
discovered, for example the dendritic protein Neurogramin whose CSF levels 
correlate well with cognitive decline and AD progression [68]. Nevertheless, the 
final goal would be the discovery of an AD biomarker with high sensitivity, 
specificity and safety that should be less invasive than those present in CSF, such 
as a blood biomarker [69]. 
Despite the progresses in the knowledge of AD pathophysiology, the disease is still 
incurable. So far, the medical treatment includes the cholinesterase inhibitors 
(such as donepezil, galantamine and rivastigmine) [3] and the N-Methyl-D-
aspartate (NMDA) receptors blocker memantine [4]. Even if the standard therapy 
provides some cognitive benefits and symptomatic relief, especially at the 
beginning of the decline, they do not alter the progression of the disease. For this 
reason, new treatments are urgently needed to stop the spread of AD over the next 
few years, even though the cause of the disease till remain unclear and difficult to 
reveal. 
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2. Amyloid beta (Aβ) 
Most of the AD clinical trials pursue the goal to recover or at least slow down the 
cognitive decline in dementia patients. To defeat AD, the main strategy works 
towards the reduction -or even elimination- of the Aβ peptide from the affected brain 
especially acting on its clearance [70]. 
Why Aβ is considered the keystone of AD pathophysiology?  
Which are the toxic effects and the ways of action of Aβ? 
The following section tries to answer the questions above by giving an in depth 
examination of Aβ peptide as causative factor in AD development. 
 
2.1 Aβ discovery 
AD research had remarkable progresses in the 1980s, thanks to the dedication of 
some scientists who tried to understand the biochemical nature of the amyloid 
deposits. One of those researchers was Dr. G.G. Glenner, who worked at the 
University of California in San Diego (UCSD). In 1982, his lab (which was actually the 
first to create an AD brain bank) opened a position for a job aimed to identify the 
protein(s) forming the senile plaques. That is how Dr. Wong joined the Glenner’s lab 
and so their collaboration started; at first they examined meninges from human AD-
affected brains because of the abundance of amyloid deposits in these membranes 
[71]. Two years later, their efforts and hopes were rewarded by the discovery of a 
protein specifically present in donated brains of AD patients compared to controls. 
They isolated a 4,2 KDa protein, which was fractionated by High Performance Liquid 
Chromatography (HPLC) into two peaks, β1 and β2, perhaps due to a proteolytic 
cleavage of the newly called β-protein. This protein had a β-pleated sheet structure 
established by polarization microscopy [28] and this conformation was very similar 
to that determined by X-ray diffraction in earlier studies [72]. The resulting protein 
was also sequenced as far as residue 24, thus obtaining the N-terminal sequence of β-
protein [28]. In the same period Glenner and Wong found out a correlation between 
AD and Down Syndrome (DS); the amyloid plaques present in AD brains were the 
same to those included in DS affected brains, which is in line with the early sign of 
dementia in patients with trisomy 21. Thus, it has been speculated that the β protein-
coding gene was located on chromosome 21 [73]; these findings were both confirmed 
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and improved in Masters et al. paper published in 1985 [74], paving the way for the 
future studies on Aβ.  
 
2.2 Aβ overview 
Nowadays the senile plaques-assembling protein is called Amyloid Beta or A-beta 
(Aβ). It is actually a peptide, rather than a protein, because of its variable length that 
changes from 38 to 43 residues [75]. No gene encodes for Aβ peptide, but it derives 
from the cleavage of the amyloid precursor protein (APP). The human gene of APP 
was cloned in 1987 by several labs independently [76]; [77]; [78]; [79]; it is highly 
expressed in the brain, as expected, but it is also ubiquitously expressed in many 
different tissues [32]. APP belongs to the APP family, which also includes the genes 
encoding others APP-like proteins (APLPs), such as APLP1 and APLP2. These APP 
proteins share a similar structure organization. In particular, APP is a type I single-
pass trans-membrane protein characterized by a large extracellular domain and a 
short C-terminal tail. Among the APLPs, APP is the one with the Aβ domain that is 
localized in the trans-membrane portion of the protein interacting directly with 
cholesterol and sphingolipid-enriched microdomains within plasma membrane. The 
interplay between lipid rafts and APP is known to modulate the canonical APP 
processing, both non-amyloidogenic and amyloidogenic [80]. Indeed, APP undergoes 
to sequential cleavages by several proteases - named α- β- and γ-secretases - either 
preventing or allowing Aβ formation. The α-cleavage occurs within the amyloid 
region thus excluding Aβ peptide to the end products derived from the non-
amyloidogenic pathway.  Alternately the full length APP is cleaved by β-secretase 
(BACE1) into the soluble secreted APP (APPsβ) and C-terminal fragment-β (CTFβ); 
the latter undergoes γ-cleavage resulting in the release of both APP intracellular 
domain (AICD) and Aβ peptide in the extracellular space (amyloidogenic pathway) 
[47].  
Since the Aβ deposition drives the formation of the extracellular senile plaques, it is 
believed for a long time that the peptide was exclusively released outside neurons. 
Even though the extracellular cleavage of APP is the most frequent mechanism 
driving the Aβ formation, recent studies on transgenic mouse and human AD/DS-
affected brains have highlighted an unusual intraneuronal way of Aβ release [81]. It 
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seems that the deposition of the peptide inside the cells is the primary steps towards 
Aβ plaques deposition. As both APP and BACE1 are integral membrane proteins, they 
are usually secreted along the classical ER-Golgi pathway. Although APP and BACE1 
are sorted into distinct organelles, it has actually been described an interaction 
between APP and BACE1 that takes place in Golgi and/or endosomes, depending on 
which neuronal part (dendrites, axon or soma) is considered [82] [83]. Further 
studies have also pointed out the reuptake of extracellular Aβ through alpha7 
nicotinic acetylcholine receptors as an additional mechanism implicated in the 
deposition of Aβ inside the cells [84].  
Despite its different release sites, Aβ is always produced as monomer by the 
proteolytic cleavage of APP. Thus, the amyloid plaques formation is a multi-step 
process involving several levels of aggregation that leads to various Aβ species. 
 
2.3 Aβ structure & assembly 
The most common forms of Aβ peptides released from neurons are Aβ1-42 and Aβ1-40 
that differ in the absence or presence of two extra C-terminal residues (Ile41-Ala42)  
[85]. Normally, both forms are present in brain parenchyma with Aβ1-40 in excess 
than Aβ1-42 (9:1) [86]. The latter seems to be more prone to aggregate in vitro [87] as 
well as in vivo, confirmed by the fact that the amyloid plaques found in AD patients 
are mostly constituted by this form of the peptide [88], [89]. However, all the Aβ 
isoforms share a common structure that makes the peptide unstable and prone to 
aggregate [90] [91]. Aβ belongs to a class of proteins called “naturally unfolded” that 
lack of a determined secondary and tertiary structure under physiological conditions 
[91]. In fact, NMR studies have shown that monomers of Aβ1-42 or Aβ1-40 possess no 
α-helical or β- sheet structures and they exist predominately as random extended 
chains [92]. The Aβ dynamics relies on these structural features that eventually lead 
to an altered conformation of the peptide resulting in the formation of aggregates 
[91]. Aβ aggregation and fibrillation are processes that are commonly related to AD 
pathogenesis [93]. As all the “naturally unstructured” proteins, aggregation of Aβ 
monomers proceeds through the formation of a partially unfolded intermediate. This 
species can contain different amounts of ordered structures representing the first 
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steps of the aggregation process. The second step is the formation of oligomers 
including soluble oligomers, protofibrils and proto-aggregates. A “nucleation-
dependent polymerization” drives the subsequent aggregation of Aβ starting from a 
kinetically disfavored nucleus. Once a critical nucleus size has been generated, the 
conditions change in favor of a progressively addition of small oligomers to the seed 
leading to fibril generation [94], [95]. Thus, some transition species such as dimers, 
trimers and small aggregate are formed before plaques generation. These oligomeric 
form of Aβ is reported to be the primary toxic specie for neurons [96]–[98], [99]. The 
cytotoxicity seems to rely on its structures, which is rich in beta-strands making the 
oligomers highly hydrophobic and able to interact with different cellular components 
[100].  
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3. Aβ neurotoxicity 
 
A plethora of experimental evidences have showed the cytotoxic effects induced by Aβ 
on single neuronal cells as well as on network circuits. To study the several ways of 
action by which Aβ triggers AD pathology, many culture systems and transgenic 
mouse models have been used so far. Since the Aβ sequence differs by three 
amminoacids between human and rodent, the latter lacks of senile plaques during its 
normal aging [101]. Thus, the murine amyloidopathy is usually achieved by the 
overexpression of familial AD (FAD)-associated mutant form of human APP (hAPP) 
[102]. In Aβ overexpressing transgenic mice, an age-dependent Aβ-overproduction 
and the resulting plaques maturation are commonly detected. Besides the over 50 
hAPP transgenic mice currently in use, other mouse models have been generated to 
elucidate the pathogenic mechanism of AD; these include mutant PS1, PS2 and Tau 
transgenic mice and mouse models generated to developed both Aβ-and Tau-
pathologies [103]. Although synaptic impairment followed by neuronal loss are 
present, the overall pathological hallmarks of AD could not be simply recapitulated 
by the overexpression of human mutated genes implicated in the pathogenesis of the 
disease. However, much of what we know about the development and progression of 
AD comes from the study of these mouse models.  
In vitro model systems of Aβ-overproduction are also achieved by the exogenous 
application of Aβ (synthetic or natural secreted form) on acute brain slices 
preparations or cultures of neuronal cells. The overexpression of APP, β- and γ-
secretases is another way to overproduce the amyloid peptide in cell systems. 
After the discovery of Aβ as the major component of senile plaques, genetic evidences 
led to the concept that Aβ itself is able to initiate the cascade of events involved in AD 
pathogenesis. This concept is well explained by the so called “amyloid hypothesis” 
which was firstly proposed by Hardy [31],[33] and contemporaneously by Selkoe [32] 
in 1991. This Aβ-centric philosophy has become the driving force into AD research 
and therapies development until now. The “amyloid cascade hypothesis” is structured 
around a sequence of pathogenic and neurotoxic events that eventually lead to AD 
(Fig. 3.1). 
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Aβ-overproduction and accumulation in the brain parenchyma are the trigger events 
proposed by Hardy and Selkoe [104]. The increase of the extracellular release of Aβ 
could be explained in patients with familial or late-onset AD, in which missense 
mutations occur in genes (PS1, PS2, APP) that are crucial for Aβ production [105]. 
However, the causes underlying the onset of the sporadic form of the disease are not 
yet fully understood. Although it involves a strong genetic predispositions [106] 
sporadic AD is still considered a multifactorial disease.  It has been hypothesized that 
the pathological rise of Aβ in certain cerebral areas may be due to an imbalance 
between production and clearance processes of Aβ [70], [107]. The peptide has been 
found not only in the brain interstitial fluid (ISF) [108] but also in plasma and CSF 
of healthy people and AD patients [109]. However, by measuring the CSF 
concentration of labeled Aβ1-40 and Aβ1-42, Mawuenyega and colleagues were able to 
measure both Aβ production and clearance rate in AD sufferers compared with age-
Figure 3.1 - The Amyloid Cascade Hypotesis 
Flow chart summarising the Amyloid Cascade Hypothesis, where the formation of Aβ oligomers are 
the initiating event in Alzheimer’s Disease pathology. Modified from Selkoe and Hardy (2016).  
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matched controls. As a result of a stable production but a decreased clearance of Aβ, 
the clearance process is impaired during the disease [107]. This may be related to the 
dependence of Aβ clearance process from the ApoE isoforms in particular from the 
ApoE ε4, which is the major genetic risk for sporadic AD [110]. Also, the half-life of 
Aβ within the ISF is doubled in PDAPP older mice compared to younger, revealing 
that the ability of the brain to clear Aβ decreases with age [111].  Whatever the mode 
by which the amyloid homeostasis will become unstable, the pathological result is an 
increased level of the peptide over the picomolar concentration found in physiological 
conditions [111], [112]. According to the “amyloid hypothesis” and data from 
oligomerization studies, increased Aβ brain concentration triggers the accumulation 
of higher order forms of the peptide derived from monomers aggregation. This 
process is crucial for the cell damaging effects caused by the peptide. Indeed, among 
the several isoforms of the peptide, ranging from endogenous monomers to fibrillar 
elements, oligomers are reported to be the Aβ species with the higher grade of toxicity 
[113]. The Aβ active pool with toxic potential is mainly composed by small oligomers 
such as dimers and trimers [98]. It has been described that the application of fibril 
free-synthetic preparation of Aβ [97], oligomers derived from cells expressing human 
APP [99] or directly extracted from AD brains [114] induce cell viability impairment 
and synaptic transmission depression both in vivo and in vitro. In 2002, Selkoe 
described AD as “a synaptic failure”, pointing out the role of Aβ as a synaptotoxic 
element in pathological conditions. Indeed, synaptic dysfunction and loss of dendritic 
spines have been described as the early symptoms that lead to neuronal death and 
cerebral atrophy typical of AD-affected brains. The mechanism by which Aβ would 
exert this action is not yet fully understood, however numerous evidences indicate 
that pathologically Aβ levels may indirectly cause a partial block of NMDA receptors 
(NMDAR) and induce Long-Term Depression (LTD). The magnitude of the NMDAR 
activation is fundamental for the regulation of the excitatory synaptic transmission, 
as it can induce either Long Term Potentiation (LTP) or LTD. The outcome varies 
depending from the extent of the intracellular calcium rise in the dendritic spines and 
the downstream activation of specific signaling pathways [115]. 
LTP is defined as the long-lasting strengthening of synapses following high-frequency 
stimulation (tetanus) of afferent fibers. It is characterized by a strong activation of 
NMDAR that mediated an intracellular calcium flux responsible for AMPA insertion 
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at post-synapses and growth of dendritic spines (called synaptic potentiation). 
Conversely, LTD requires a long low-frequency synaptic signal that leads to spine 
shrinkage and synaptic loss. This is fundamental to counteract the excitotoxicity 
caused by a persistent LTP. Oligomeric Aβ depress the hippocampal synaptic activity 
by enhancing LTD [116] and impairing LTP [99], [114]. The mechanism by which 
LTD would be facilitated by Aβ is still unclear, however it may involve different ways 
of action: desensitization of NMDAR caused by the block of glutamate uptake at 
synapses and the resulting increase of glutamate levels at the synaptic cleft, activation 
of extrasynaptic NMDAR or endocytosis of NMDAR through the activation of the α-7 
nicotinic receptor and PP2B, a calcium sensitive enzyme that regulates NMDA 
receptor transmission and synaptic plasticity [116].  
Although the effects of Aβ on excitatory synaptic transmission have been extensively 
studied, fewer investigations have focused on the effects of the peptide on more 
complex networks. Neuronal circuits are formed by synaptic interactions among 
excitatory, inhibitory and modulatory cells that cooperate to maintain a balanced 
activity. . Recent studies pointed out that amyloid depositions begin to form in 
specific brain cortical and subcortical regions involved in learning, memory and 
emotional behavior. These areas are anatomically and functionally connected and 
represent the brain system called “default network”. It includes areas associated with 
the medial temporal lobe memory system, such as entorhinal cortex and 
hippocampus, which are reported to be impaired in AD patients. Cognitive active 
tasks do not engage the default mode, which is most active during passive state and 
cognitive baseline tasks that direct attention away from external stimuli. Peculiar 
metabolic properties set the default network apart from other cerebral regions; it is 
characterized by high glucose metabolism and high regional blood flow. Functional 
MRI (fMRI) analysis of patients with early mild-to-mild AD showed reduced network 
activity compared to healthy conditions [117], [118] in line with the brain 
hypometabolism found in AD sufferers that correlates well with the progression of 
the disease [119]. Aβ oligomers alter the excitatory transmission via several NMDAR-
dependent processes, however it has also been described a GABAergic dysfunction in 
hAPP and PS1 double transgenic mice (hAPP/PS1) that induces an alteration in 
synaptic inhibition of neurons situated in the vicinity of amyloid plaques. In the same 
study, calcium imaging experiments performed on cortical circuits also showed an 
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imbalance between hypoactive and hyperactive neurons than non-transgenic controls 
[120]. In addition, reduced expression of the Nav1.1 voltage gated sodium channels 
subunit (SNC1) in human amyloid precursor protein (hAPP) transgenic mice prevents 
the action potential propagation in parvalbumin interneurons leading to a GABA 
deficit release [121]. Thus, both excitatory transmission and synaptic inhibition would 
be modified by high Aβ levels causing the shift from NMDAR-dependent signaling 
cascades, which include synaptic potentiation, towards the induction of LTD and 
synaptic loss. These evidences sustain the hypothesis that Aβ may cause network 
instability promoting the disruption of neuronal synchrony, which in turn leads to an 
epileptiform activity. AD sufferers have indeed a higher risk to develop clinical 
seizures during the course of their illness [122]; this epileptiform behavior also occurs 
in mice models of amyloidopathy which show non-convulsive seizure activity [123], 
[124], [125], [126]. Data obtained from Aβ-overexpressing mice have recently 
reported alterations in the intrinsic properties of excitable cells that point towards an 
Aβ-dependent neuronal hyper-excitability [127], [128], [129], [130], [131], [132], 
[133], [134]. The increase in the action potential firing rate has been reported to be 
the main change found in AD-mouse models [127],[129],[131],[132]. A depolarization 
of the membrane potential by about 10 mV has been suggested to be one of the 
possible mechanisms of the increased cellular hyper-excitability found in APdE9 
mice, which also display seizures during EEG-video recordings [126]. Amyloidopathy 
seem related to a decrease in the width of action potentials; patch-clamp recordings 
performed by isolating nucleated outside-out macropatches from the cell bodies of 
CA1 pyramidal cells of PSAPP mice have shown that the action potential (AP) 
narrowing correlates with a 50% decrease in sodium voltage-gated currents related to 
control condition [127]. Narrower AP has also been observed in CA1 pyramidal 
hippocampal neurons of Tg+ CNRD8 mouse; in this study authors suggest that the 
alteration of the AP waveform is mainly due to an increased expression of Kv3 
channel, which are responsible for the repolarization phase of the action potential 
[129]. Decreased width of action potentials was also identified in PDAPP mice aged 9-
10 months; conversely older PDAPP mice (20-23 months) display a normal firing 
activity but a narrower AP and reduce peak compared to age-matched wild-type 
control mice. Moreover, an increase of the amplitude of the fast spike after-
hyperpolarization (AHP) might explain the lack of an altered firing activity in these 
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mouse models of AD [134]. Furtermore, pre-treatment (2-5 hours) with 500 nM of 
oligomeric Aβ in CA1 hippocampal slices of wild type mice aged 4-5 weeks alters the 
action potential subtreshold, which is more hyperpolarized, but depress AHP leading 
to a net hyper-excitability of cells without affecting the firing rate of neurons [133]. In 
the majority of these studies CA1 hippocampal region is the main brain area studied, 
as implicated in memory formation and plasticity. However, hippocampus exchanges 
information through the enthorinal cortex, which is the input-output structure that 
connects neocortex with the perforant pathway of the hippocampus. Analyzing two 
different cell-types of the enthorinal cortex in Tg2576 transgenic mice, Stellate Cells 
(SCs) and Fan cells (FCs), Marcantoni and colleagues described a hyper-excitability 
behavior of FCs with an enhanced AHP and shorter action potential width compared 
to wild-type mice. Tg2576-FCs also exhibited a decreased firing frequency during 
mild and higher depolarizations whereas SCs display a normal excitability when 
stimulated with increasing current injections [135].  
All the above evidences support a toxic role of Aβ on nervous system that is composed 
by billion of synaptic connections between different types of cells whose outputs may 
be excitatory or inhibitory. The neuronal network physiology relies on the synaptic 
integration of signals that must be constant and efficient. Aβ appears to be a 
disruptive element of the network homeostasis in pathological conditions by altering 
the degree to which neuronal activities are correlated.  
 
 
4. Targeting Aβ 
 
In the last two decades Aβ has been the primary focus for the scientific community 
regarding AD research and treatment. Indeed, among 105 agents included in the 
Alzheimer’s drug development pipeline, half of them specifically targets Aβ as both 
antibodies directed at different forms of the peptide (monomers, oligomers, fibrils) 
and as β-secretase inhibitors. So far, the key factors involved in AD development - 
including Aβ - have been partially highlighted. There is currently an urgent need to 
understand how these factors temporally and functionally cooperate to cause the 
disorder in order to design a successful therapy. 
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Even though AD is an incurable disease, some medications and alternative-approved 
therapies are commonly used to treat dementia patients. Below there is a summary of 
the prescription drugs and other interventions used for helping AD people as well as a 
summary of the current AD-clinical trials and their outcomes. 
 
 
4.1 AD Approved Therapies  
Although there are different parameters to identify the multiple cognitive decline 
levels in AD patients, the disease progression is well represented by three principal 
stages: mild cognitive impairment (MCI), moderate AD and severe cognitive decline 
(or late dementia[136]; [137]. The commonly used medications are usually more 
suitable for one of the many progression stages of the disease. Due to the low levels of 
acetylcholine (ACh) detected in AD affected brains, the first drugs developed were the 
cholinesterase inhibitors, which aim to raise the ACh levels in the brain by blocking 
the cholinesterase activity. These medications are usually prescribed for patients with 
beginning AD, since they help to delay the worsening symptoms by stabilizing the 
cognitive functions [3].  
A drug known as memantine, a NMDA receptor antagonist, is specifically used for the 
treatment of moderate to severe AD. Blocking the pathological activation of NMDA 
mainly improves the day-by-day functions thereby delaying the onset of care 
dependency, a benefit for both patients and caregivers [4], [68].  
Many dementia patients also show behavioral disturbances such as aggressiveness, 
depression, agitation, wandering, anxiety and sleeplessness that could be managed by 
several prescription drugs. However, unwanted side effects can be caused by these 
medicines that accelerate cognitive decline and become consequently not effective. 
Thus, non-pharmacological approaches are emerging as complementary therapy in 
order to improve the quality of life of AD patients. Randomized controlled trials have 
shown strong effects of psychosocial interventions on dementia patients treated for 
agitation. Music therapy, meaningful and pleasant activities as well as social 
interaction (both real social life and doll-therapy) are useful alternative-therapies for 
agitation with short- and long-term positive effects. The idea behind the 
complementary therapies is to reconnect patients to their physical and social 
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behavior and also to slow down the distress and anxiety due to an uncertain and 
unfamiliar environment. Indeed, many people with dementia eventually move into 
care homes or hospitals when caregivers cannot manage anymore the growing need 
of these individuals. Also, due to the progressive brain impairment, AD patients may 
not recognize family members causing insecurity and anxiety feelings. These 
manifestations, including depression, could be managed by a variety of non-
pharmacological measures together with the psychological support such as the 
cognitive stimulation therapy or the cognitive training, as the drug treatment is 
almost ineffective [138], [139].  
All these interventions are very useful to increase the quality of life of AD sufferers 
and also to manage their feelings about the real world. Even so the final goal would be 
to stop the disease progression before the neurodegeneration becomes irreversible 
but unfortunately there is still no cure for AD. Despite this, more than 400 clinical 
trials are currently active looking for new compounds able to effectively manage AD.  
 
4.2 Current Clinical Trials (2017) 
Because of the growing worldwide cases of dementia and the high costs for AD health 
care, a large number of AD clinical trials start every year in the world. They evaluate 
new medications and non-pharmacological therapeutic approaches to recover the 
cognitive abilities or even to stop the neurodegeneration in affected brains. In 2017, 
there are 105 drug candidates in the AD pipeline divided into three phases (I, II, II) of 
drug development. Aβ is the primary target of these agents since they aim to reduce 
the peptide amount in the brain by different mechanisms [2]. The most developed 
strategies consist in targeting Aβ by blocking either β- or γ-secretases activity or by 
using antibodies against Aβ. So far, studies regarding the development of proteases 
inhibitors have been hampered due to the substrate promiscuity of both β- or γ-
secretases. Blockage of BACE1 activity leads to very toxic effects due to the important 
physiological roles of its substrates, including its role in the regulation of axon 
myelination in the peripheral nervous system (PNS) by the proteolytic processing of 
Neuregulin-1 (NRG1) and its involvement in the regulation of axonal guidance [140]. 
In the same way, it has been demonstrated that Notch is one of the targets of γ-
secretases [141]. Notch is a master gene involved in embryonic and adult 
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development; it regulates Neural Stem Cells (NSC) proliferation, neuronal 
differentiation as well as synaptic plasticity and dendritic arborization [142]. 
Recently, passive and active immunization are the most pursued AD approaches with 
the higher number of drug candidates in phase III (50% of the total agents). Passive 
immunotherapy uses human monoclonal/polyclonal antibodies against Aβ that bind 
specific sub-regions of the peptide to avoid the oligomerization. The antibody could 
be directed at soluble monomers or more aggregated species of Aβ (soluble or non-
soluble). Induction of immunity after the exposure to Aβ peptide (full-length or a 
segment) by injection is instead called active immunization. Even if this procedure 
provides a prolonged antibody response, it has preceded more slowly than passive 
therapy due to the adverse effects and responses in elderly patients [143]. 
Nevertheless part of these studies is ongoing; some of the pipeline vaccines are able 
to induce an appropriate immune response to Aβ peptide with good tolerability and 
without dangerous side effects [141], [2]. 
Neurotrasmitter regulation is another relevant mechanism of action of the developing 
drugs. 30% of phase III- and 20% of phase II-agents [2] aim to either activate or 
inhibit some neuronal receptors implicated in AD pathogenesis and progression. 
Muscarinic and nicotinic receptors agonists as well as serotonin and histamine 
receptors antagonists are those currently under examination for their therapeutic 
potential [141]. 
Together with amyloid plaques, NFTs are the other pathological hallmark of AD 
affected-brains thus several approaches to target tau pathology have been developed 
in recent years. The adopted strategies work towards improvement in Tau protein 
homeostasis: inhibition of Tau aggregation, microtubule stabilization, reduction of 
Tau-phosphorylation and accumulation to avoid NFTs formation. Despite that, due to 
the essential role of microtubule dynamics in neuronal functioning, therapeutic Tau-
targeting therapies are usually bound to fail [144], [145].  
AD-affected brains are characterized by an altered cerebral functioning, where 
multiple molecular processes are compromised, such as neurotransmitter 
transmission, caspases activation, ROS production ect. New approaches that confer 
neuroprotection against the deleterious mechanisms prompting neuronal dysfunction 
are recently emerging. Multiple studies have revealed a decrease in Brain-derived 
neurotrophic factor (BDNF) levels in AD patients ([146] in addition to a drop in 
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Nerve growth factor (NGF) levels in mouse model of ageing [147] [148]. Both BDNF 
and NGF belong to the neurotrophins family, a group of growth factors and secreted 
proteins implicated in neuronal surviving, proliferation and differentiation. In 
addition NGF plays an important role in the maintenance of cholinergic neurons. 
Thus, the activation of BDNF signaling or the ex vivo NGF-gene delivery to AD 
patients are some examples of the more recent neuroprotective strategies adopted for 
dementia treatment [141], [149]. It is also well documented the association between 
oxidative stress and AD which have led to the introduction into the AD pipeline of 
therapies focused on the administration of antioxidants such as Vitamin A, C, B12, 
omega3 ect [150]. 
(for further information please visit clinicaltrials.gov) 
 
4.3 Outcomes from Aβ-trials 
Targeting Aβ is the most supported strategy to treat AD due to the centrality of the 
peptide in the initiation and progression of the neurodegeneration. Currently, the 
amyloid hypothesis addresses half of the agents currently in phase III. These drug-
candidates should be either approved or rejected between 2016 and 2020; here’s a 
summary of the Aβ-phase III outcomes that have already been published.  
As mentioned before, Aβ-targeting therapies attempt to decrease the amyloid peptide 
levels in the brain by blocking the proteases activity involved in the APP-processing 
or by using passive or active immunization. The antibodies used to trigger an 
appropriate Aβ IgG response have recently been improved and newly tested as 
second generation vaccines. The goal has been to avoid the serious side reactions of 
the first generation vaccines, thus it has been designed a shorter Aβ peptide segments 
directed at the N-terminal end of the Aβ protein, which was supposed to contain a B-
cell epitope while avoiding the T-cell activation so meningoencephalitis. Currently 
developing vaccines seem to have acceptable safety and tolerability, only one in nine 
agents is undergoing phase III study; it has reported to have good Aβ IgG response 
and no side effects. 
As for the developing therapies based on passive immunization, there are currently 
three monoclonal antibodies against Aβ in phase III. The higher expectations were 
for the Eli Lilly & Co. EXPEDITION3 program, the phase III study designed to assess 
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the effect of the developing drug LY2062430 called solanezumab. It is the humanized 
analog of the murine antibody m266.2, whose mechanism of action differs from 
others N-terminal antibodies since it favors the peripheral Aβ clearance by altering 
the equilibrium of the native peptide between the central nervous system and 
periphery [151]. Solanezumab is a humanized monoclonal antibody that specifically 
binds soluble Aβ, in particular monomers. Phase I and II randomized, placebo-
controlled studies confirmed its safety and tolerability in patients with mild to 
moderate AD. Magnetic resonance images and analysis on cerebrospinal fluids of AD 
sufferers did not show any abnormalities. However, 2 of the 4 subjects to whom was 
given given the highest concentration (10-mg/kg) of solanezumab reported asthenia. 
Previous AD-clinical trials - γ-secretases-targeting therapy and passive 
immunotherapies - have also reported asthenia as side effect. These symptoms could 
be related to a decreased concentration of the endogenous Aβ suggesting a putative 
physiological role of the native peptide. In phase III EXPEDITION 1 and 2 studies, 
2052 people affected of mild to severe AD were recruited. Although the drug has 
continued to be safe, the overall EXPEDITION showed no improvement on the 
primary outcome measures ADAS‐Cog11 and ADCS‐ADL (Alzheimer’s Disease 
Assessment Scale–Cognitive subscale (ADAS‐Cog11) and Alzheimer's Disease 
Cooperative Study - Activities Of Daily Living (ADCS‐ADL)). However, a subgroup of 
patient with mild AD displayed reduced cognitive decline after infusions of 400 mg of 
solanezumab once a month for 80 weeks [151]. Thus, the third phase of the 
EXPEDITION study started at July 2013 aiming to analyze the effect of the drug only 
in the group of mild AD. Unfortunately, in November 2016 Eli Lilli announced that 
Solanezumab missed primary endpoints of the trial leading to the withdrawal of the 
study. However, the Phase III study of the drug sponsored by Biogen is still ongoing. 
Aducanumab is a human monoclonal antibody against Aβ aggregates, including 
oligomers and fibrils. The drug was originally derived by the Neurimmune company 
(Switzerland) from healthy donor with good cognitive functions. A double-blind, 
placebo-controlled phase I randomized trial (PRIME) started in 2012 and 165 
patients with prodromal or mild AD (Aβ positive to PET scan) were randomized and 
treated with increasing concentrations of aducanumab by intravenous infusions. The 
outcomes were positive: the drug is able to penetrate into the brain and reduce Aβ 
aggregates in a dose- and time-dependent fashion as measured by PET-scan. It has 
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good safety and tolerability with some side effects such as amyloid-related imaging 
abnormalities (ARIA), headache, urinary tract infection and upper respiratory tract 
infection [152]. Phase III began in August 2015 and it set to run until 2022. 
Another promising phase III drug was a BACE inhibitor designed by Merck Company 
named Verubecestat (BIIB037). It is a small-molecule BACE1 inhibitor that have 
shown positive effects in reducing the celebrospinal fluid, plasma and brain 
concentrations of different isoform of Aβ, such as Aβ1-40 and Aβ1-42, in rats and 
monkeys after both acute and chronic treatment of the drug. Phase I study started in 
2011, 78 patients with mild to moderate AD were recruited in order to test the safety 
and tolerability of the drug.  Verubecestat was reported to have been generally safe 
and to have reduced the brain Aβ concentrations of AD sufferers. Phase II/III 
EPOCH study started in November 2012 with an initial recruitment of 200 mild-to-
moderate AD patient then expanded to phase III with a total of more than 2000 
participants. In February 2017, few months later the Eli Lilli announcement, Merck 
Company halted the EPOCH study for lack of efficacy. As reported by the website of 
the company: “Merck is stopping the study following the recommendation of the 
external Data Monitoring Committee (eDMC), which assessed overall benefit/risk 
during a recent interim safety analysis, and determined that there was virtually no 
chance of finding a positive clinical effect.”  
Recently, Axovant Company announced negative topline result of its Phase III 
MINDSET clinical trial. MINDSET study tested the therapeutic potential of the 
investigational drug intepirdine. It is a potent antagonist of the 5-HT receptor that 
promotes the release of acetylcholine in the brain. Despite the well tolerability, 
intepirdine do not improve the cognitive impairment of AD patients 
(http://investors.axovant.com/news-releases/news-release-details/axovant-
announces-negative-topline-results-intepirdine-phase-3) 
The failure of these three major clinical trials, together with the halting of past 
studies, adds the growing concern in the scientific community that the amyloid 
hypothesis may not be true, highlighting the necessity to reassess the centrality of Aβ 
in AD pathogenesis. 
 
  
 29 
5. Reassessment of the amyloid hypothesis 
…or reconsideration of the Aβ role? 
 
The amyloid hypothesis is the subject of the modern scientific debate because of the 
failures of Aβ-targeting therapies as well as some evidences that appear to undercut 
the centrality of the peptide in AD pathogenesis. As described before, the reduction or 
the tout court elimination of Aβ from AD-affected brains not only is ineffective to 
recover the cognitive impairment caused by the disease but also causes numerous 
side effects that led to the clinical-trials termination before the planned completion. 
The reasons underlying the lack of a successful therapy able to manage AD are likely 
due to the complexity of the disease that manifests itself at stages too far advanced to 
be able to restore the neurodegeneration. Indeed, some suggest that the disease is not 
targeted early enough, thus some clinical interventions are currently testing anti-Aβ 
drugs on elderly people who do not yet show symptoms of AD, such as cognitive 
impairment or dementia. The A4 study sponsored by Eli Lilly Company is an anti-Aβ 
AD trial that aim to test whether solanezumab can slow the progression of the disease 
in elderly people positive to amyloid pathology, measured by positron emission 
tomography (PET) imaging, but still asymptomatic. (ClinicalTrials.gov Identifier: 
NCT02008357). In addition, The DIAN and the API Colombia study have the 
purpose to analyze the effects of anti-Aβ treatments on pre-symptomatic elderly 
people at risk for familial AD [153]. Positive outcomes of these studies will validate 
the amyloid hypothesis; if they are not successful it will be necessary to rethink our 
approaches to the disease. 
The key factor of the amyloid hypothesis is surely the Aβ peptide described as the 
primary trigger of the subsequent pathogenic events occurring in AD development, 
including Tau pathology. However, it is still unknown the biochemical pathway that 
links amyloid plaques to neurofibrillary tangles (NFTs) formation and how they are 
temporally involved in the disease progression. Tau pathology appears to be well 
correlated, both temporally and spatially, with neuronal loss and AD symptoms 
development than amyloid plaques [154]. Also, mutant tau transgenic mice display 
NFT-like neuropathology in absence of amyloid pathology. However, tau deposition 
is enhanced in double mutant (APP/Tau) transgenic mice whereas the development 
of amyloid deposition takes place at the same age of the parental strain (Tg2576 
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hAPP transgenic mice) [155]. Moreover, injection of a synthetic Aβ preparation into 
the brain of mutant human Tau–expressing mice led to a marked increase in 
neurofibrillar tangles [144]. Although the spreading of amyloid plaques does not 
precisely correlate with the neurodegenerative symptoms of AD, the genetic 
evidences strongly support Aβ as a fundamental toxic element in the disease 
initiation. The familial form of the disease is caused by mutations in genes involved in 
Aβ production, such as APP, PS1 and PS2 [156]; moreover Down syndrome patients 
with an extra copy of the APP gene develop age-related dementia and plaques 
deposition [157]. An assumption of the amyloid hypothesis is that Aβ is just an 
accident of APP metabolism and its production is a pathological process, not 
physiological. So far the scientific community has been focused on the toxicity of the 
amyloid peptide, discarding the idea that Aβ may have a potential biological 
function(s) during normal conditions. APP is early expressed during development 
[158] and Aβ is also physiologically produced by the brain since the very beginning of 
embryonic life in mammals and continues for the whole life of the organism [159]. 
Taking advantage from the microdialysis technique, it has been possible to measure 
the in vivo levels of Aβ; it is found to be at picomolar concentrations in human 
healthy brain as well as in the interstitial fluids (ISF) of wild-type mice [160], [112]. 
Interestingly, by simultaneously measuring the electroencephalographic (EEG) 
activity and ISF Aβ levels in the hippocampus of Tg2576 mice, Cirrito and colleagues 
were able to demonstrate a correlation between Aβ brain concentration and synaptic 
activity [160]. The amyloid levels in ISF are dynamically regulated indirectly by 
neuronal activity, that control the APP cleavage operated by BACE enzyme [161] and 
directly by synaptic activity, which also mediates the APP endocytosis [162]. Thus, 
brain activity physiologically regulates the level of the peptide in the ISF allowing an 
overall low Aβ concentration that is maintained over time and may be involved in 
normal brain physiology. Aβ synaptic modulation might be interpreted as a defense 
mechanism by which neurons prevent the toxic effects caused by the oligomeric form 
of the peptide at high concentrations. This is likely true in the light of the dose-
dependent effects induce by Aβ. It is indeed proposed a negative feedback regulation 
of neuronal activity that rely on Aβ production and that could have a role in brain 
homeostasis maintenance [161]. This suggestion supports a biological function of 
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endogenous Aβ that could clarify why the absence or the reduction of native Aβ 
causes abnormalities and side effects both in humans and rodent [159]. 
It is therefore essential to reassess the role of endogenous Aβ in light of the evidences 
towards a possible physiological function of the peptide. This may help to clarify the 
sequence of the major pathological events involved in AD development and so to 
design successful treatments able to manage the disease. 
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 6. Aβ trophic effects 
 
Since Aβ is physiologically produced and released in the brain ISF during 
development, adulthood and aging [163], it may play a biological function in healthy 
conditions. Growing evidences push towards a modulatory role of Aβ at low 
concentrations on synaptic plasticity acting as a negative feedback signal to maintain 
the brain activity within a normal range. Kamenetz and colleagues were the first to 
propose a feedback loop regulation between neuronal activity and APP processing. By 
using organotypic hippocampal slices from APP-transgenic mice, they demonstrated 
that neuronal activity regulates Aβ production by controlling the level of BACE 
cleavage. Moreover, Aβ synthetized by APP overexpressing neurons depresses the 
synaptic activity of neighboring cells.  Thus, increased neuronal activity produces 
more Aβ enhancing the APP-endocytosis [160] or APP-processing through BACE1 
cleavage. High level of Aβ depresses the synaptic function leading to a drop in 
neuronal activity [161]. The impairment of synaptic functions caused by high levels of 
Aβ is well known and characterized, both in vivo and in vitro [93]. However, recent 
works suggest that low concentrations of Aβ could act as a positive regulator at 
synaptic level. Indeed, wild-type hippocampal slices perfused with 200 pM of Aβ42 for 
20 minutes show an enhancement of LTP that is reported to be dependent on the 
increase of transmitter release during tetanus [164]. Also, addition of 200 pM Aβ42 
rescue the LTP depression caused after APP suppression by siRNA or using anti-Aβ 
antibody suggesting a fundamental role of Aβ in LTP induction [165]. The Aβ-
dependent enhancement of synaptic plasticity and memory [166] appears to be 
mediated by α7-containing nicotinic acetylcholine receptors (α7-nAchRs) [164], [165] 
which is in line with the finding that Aβ might directly bind α7-nAchRs with 
picomolar affinity  [167]. Thus, controlling the concentration of Aβ is essential to 
modulate the effects triggered by the peptide on neuronal activity. Aβ aggregation is a 
concentration-dependent process that might be avoided decreasing the neuronal 
activity responsible for its production. Indeed, the brain ISF levels of Aβ are 
modulated not only during pathological conditions such as following hippocampus 
electrical stimulation [159] but also during physiological conditions, such as sleep-
wake cycle [108]. It has been reported an increase of ISF Aβ levels following sleep 
deprivation in human APP transgenic mice; furthermore individuals with sleep 
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fragmentation have higher risk to develop AD compared to individuals with regular 
sleep [168].  Periods of wakefulness are usually associated with an increase in 
synaptic strength whereas periods of sleep are associated to a decrease in synaptic 
strength [169]. Aβ fluctuations might have a role in this phenomenon since relatively 
small increases in endogenous Aβ amount, enhanced the release probability of 
synaptic vesicles and increased neuronal activity in neuronal cultures [170].  
Depletion of endogenous Aβ significantly reduced the cell viability of rat cortical 
neurons treated with secretase inhibitors or antibody against Aβ; however low 
concentrations of Aβ, ranging from 10 pM to 1 nM, rescue the toxic condition in a 
concentration dependent manner suggesting a crucial role of the peptide in neuronal 
survival [171]. In the same way, it has been demonstrated a neuroprotective role of 
monomeric Aβ under conditions of trophic deprivation as well as during 
excitotoxicity. This neuroprotective action was mediated by the activation of the PI-3-
K (phosphatidylinositol-3-kinase) pathway, and involved the stimulation of IGF-1 
(insulin-like growth factor-1) receptors [172].  
Some recent studies underlie a role of Aβ in neurogenic processes both in the embryo 
and in the adult brain. Both Aβ1-40 and Aβ1-42 seem to have a trophic function on 
neural stem cells (NSCs). NSCs are present in the adult human brain only in two 
regions: the subventricular zone (SVZ) and the subgranular layer of the dentate gyrus 
in the hippocampus. In vitro experiments performed on rat NSCs show that Aβ1-42 can 
directly induce neuronal differentiation without affecting cell viability or proliferation 
[173]. Another work was published asserting that Aβ can lead mouse NSCs 
differentiation and proliferation, but only in its oligomeric form [174]. Thus, the 
precise effects of Aβ on NSC are not yet clear as the experimental conditions vary too 
much between studies. It is possible that both the isoform of the peptide -monomers 
and oligomers- act as pro-differentiating elements but during different conditions, 
physiological or pathological, in order to allow the insertion of newborn neurons into 
the network. In light of this, amyloid plaques formation might be a compensatory 
mechanism of the brain by which Aβ would be trapped into aggregates in order to 
decrease its concentration. This might explain the presence of amyloid plaques in 
brains of older people with no signs of cognitive impairment or dementia symptoms 
[159].  
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Based on these data, Aβ appears to be a physiological peptide normally produced by 
the brain. It may induce negative or positive effects depending on its concentration, 
which is finely regulated by neuronal activity and follows circadian rhythms. 
Although the oligomeric form is well known to have neurotoxic effects, it is suggested 
that low concentrations of Aβ could modulate neuronal homeostasis in healthy 
conditions acting on synaptic functions as well as neuronal survival.  
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Aims of the work 
 
So far the amyloid hypothesis has mainly driven the AD drugs development; however 
most of the anti Aβ-clinical trials have been suspended due to the lack of significant 
cognitive improvements as well as to the side effects caused in AD patients in some 
studies. Although the negative outcomes of β- and γ-secretases targeting therapies 
are reasonable explained by the significant biological functions covered by such 
proteases, the reason Aβ-centric therapies fail is still unclear. Thus, to design a 
successful therapy for AD it is therefore crucial to uncover the role of soluble 
endogenous Aβ in the healthy brain. Even though the amyloid peptide has been 
extensively studied because of its association to AD, its physiological function(s) is 
now being studied in much more detail (see paragraph “Aβ trophic effects” for 
details). 
My thesis work is part of the recently emerging idea that Aβ – at low concentrations - 
is not just a toxic waste product of the brain but it might be a relevant element 
involved in the maintenance of neuronal network homeostasis.  
Our final goal is therefore to explore the effects of the monomeric Aβ1-42 peptide on 
excitable cells.  
First, we aim to assess the effects of monomeric Aβ on the excitability of immature 
cortical neurons. Starting from a preparation of pure monomers, the aggregation of 
the peptide as well as its impact on neuronal functioning is dependent on the 
monomers concentration. We intend to evaluate the effects of different 
concentrations of Aβ on neuronal activity, looking for a concentration threshold at 
which the peptide switches from being trophic to toxic.  
Among its several actions, it has been found a pro-differentiating role of Aβ on 
Neuronal Stem Cells (NSC). Since we use immature neurons as model system, we 
subsequently aim to analyze whether monomeric Aβ affects the developing process of 
these cells, in particular the electrical maturation and how it affects the neuronal 
morphology. 
Whether they are toxic or trophic, the overall Aβ effects converge towards an altered 
communication among nerve cells. Indeed, it is well described a toxic effect of Aβ at 
synaptic terminals but little is still known about the effects of monomers. It is 
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intriguing to think that also the monomeric form of the peptide may have a role at 
synapses as modulators of the communication among neurons. Thus, we finally plan 
to investigate the synaptic alterations induced by the monomeric form of Aβ on 
juvenile neurons focusing on excitatory synapses since they are more sensitive to Aβ 
levels than inhibitory synaptic connections.  
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Materials and Methods 
Electrophysiology 
Patch clamp recordings were collected using an Axopatch 200B amplifier (Molecular 
Device, CA, USA) and Digidata 1322 acquisition system. Analog-to-digital converter 
signals were digitized at 5 kHz and filtered at 1 kHz.  Patch electrodes (GB150F-8P 
with filament, Science Products) were pulled from hard borosilicate glass on a 
Brown-Flaming P-87 puller (Sutter Instruments, Novato, CA, USA) and fire-polished 
to a final electrical resistance of 5-7 MΩ. 
Whole-cell, patch-clamp recordings were performed at room temperature on primary 
cortical neurons ranging between 4 to 18 DIV. The composition of the extracellular 
solution was:  (in mM) 138 NaCl; 4 KCl; 2 CaCl2; 1.2 MgCl2 ; 10 HEPES; 10 D-
glucose (pH 7.4 – osmolarity adjusted to 300 mOsm with NaOH). 
The composition of the intracellular solution was (in mM): 126 K-gluconate, 4 NaCl, 
0.05 CaCl2 , 0.1 EGTA, 10 HEPES, 10 D-Glucose 1 MgCl2 , 3 mM ATP-Mg2+ , 0.1 mM 
GTP-Na+ (pH 7.2; osmolarity adjusted to 270 mOsm with KOH). After forming a tight 
seal (>1 GΩ) and entering the whole-cell configuration in voltage-clamp mode, the 
amplifier was switched to current clamp mode. The resting membrane potential (Vm) 
was first measured and only cells with Vm more negative of -50 mV were considered. 
In all data sets performed, pipette-capacity, whole-cell capacity and series resistance 
were compensated before each protocol whereas the liquid junction potential was not 
corrected. 
Current-clamp recordings: To elicit action potentials (APs), neurons were held at -
60 mV and stimulated with depolarizing current injections of 800 ms duration and 
amplitude ranging from 10 pA to 100 pA. To assess individual AP waveforms at 4 
DIV, the first spike fired at 80 pA current injection was analyzed, as at 80 pA of 
current injection all cells fire. AP width was measured from the threshold as the 
width at half-amplitude. The half-width value was calculated considering the AP 
width measured at 50 % of the peak amplitude. AP threshold was determined by 
analyzing phase plots as the voltage (mV) at which dV/dt surpassed 5 mV. The 
criterion for spike threshold was set at 5 V/s because this is just above the maximal 
level of dV/dt obtained by our noise injection when action potentials were not 
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initiated. AP amplitude was calculated from the holding potential (Vh) of the cell to 
the peak of the AP.   
Voltage-clamp recordings: Inward sodium currents (INa) were elicited by delivering 
a series of depolarizing voltage steps  (from −80 to +60 mV in 20 mV increments, 
800 ms duration) from an holding potential of −70 mV. INa+ was estimated by 
analytical subtraction of ionic current after addition of Tetrodotoxin (TTX; 0.3 µM) 
(Tocris) from the total current of the cell. Potassium currents (fast transient K current 
named IKA and delayed rectifier K current named IKV) are evoked by voltage steps 
from different Vh (-80 mV or - 40 mV) to -5 mV; 2000 msec duration. Briefly, IKV 
was evoked by a voltage step from – 40 mV (where IKA channels are already 
inactivated) to - 5 mV. The total outward current (which is composed by both IKA and 
IKV) was recorded by a voltage step from  -80 mV to -5 mV. IKA was isolated by 
analytical subtraction of IKV from the total potassium current (IKA + IKV) recorded in 
the same cell (Fig. 6A). IKV was measured at the end of the waveform voltage step 
whereas IKA was measured at the peak current of the test step. Both INa and IK 
values were reported as pA not normalized as  
Spontaneous excitatory postsynaptic currents (sEPSCs) recordings were performed in 
voltage-clamp mode by adding Gabazine (5 µM, Tocris) to the extracellular solution. 
The Vh was kept at -70 mV and the each recording recordings lasted >1-5 minutes. 
The detection level for sEPSCs analysis was set at 5 pA. Analysis of sEPSC frequency, 
amplitude, rise/decay time and area was performed offline by Clampfit 9.2. 
All data analysis was performed offline with Clampfit 9.2 (Molecular Device, CA, 
USA) or Origin 9.1.  
 
Aβ1-42 Depsi-peptide 
Aβ1-42 Depsi-peptide was kindly provided by IRCSS-Mario Negri Institute for 
Pharmacological Research, Milan. Aβ1-42 Depsi-peptide is obtained through solid 
phase protein synthesis (SPPS) which allows the formation of an ester binding 
between the hydroxyl group of serine 26 and the subsequent glycine. The monomeric 
form of the peptide is maintained at acid pH and -80°C for several months 
preventing the self-aggregation. The Aβ1-42 native form is obtained as pH is switched 
to neutral allowing a time and concentration-dependent aggregation of the peptide. 
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To properly obtain the native form of Aβ1-42 we switched the pH of the suspension 
buffer (distilled H2O) by diluting the Depsi-peptide solution (initial concentration 
depends from the synthesis process) in 1X DPBS w/o Mg2+ and Cl-  to a concentration 
of 100 µM and subsequently diluted in neuronal culture medium at the desired final 
concentration (10 nM, 100 nM, 500 nM). 4 DIV neurons were treated the day after 
the dissection (1 DIV) whereas 7 DIV neurons were treated at 4 DIV; in both cases 
neurons was treated with Depsi-peptide for 72 hours and the culture medium was not 
replaced during the treatment period. 
 
Primary cultures of cortical neurons  
Cultured cortical neurons were isolated by CNR - Institute of Neuroscience, Milan 
[175] and were prepared from rat embryos at gestational age 18 days (E18) and plated 
in 12-well at a density of 75’000 cells/well on glass cover slips treated with L-
Polylysine (50 µg/ml). Cultures were grown at 37°C with 5% CO2 in Neurobasal 
Medium supplemented with 2% B27, 0,25% L-glutamine, 1% Penicillin/Streptomycin 
and 0,125% glutamate for 4 days. At the fourth day in vitro (4 DIV), 500 µl of culture 
medium was substituted with 400 µl of fresh medium without glutamate and cultures 
were grown until 7, 11 or 18 DIV.  
 
Treatments 
For experiments on 4 DIV neurons, cells were treated at 1 DIV with Aβ1-42 at different 
concentrations (10 nM, 100 nM, 500 nM) for 72 hours. For experiments on 7 DIV 
neurons, cells were treated at 4 DIV for 72 hours with 10 nM Aβ1-42. During the Aβ1-42 
treatment period the culture medium was not replaced. For sEPSC recordings, 1 µM 
TTX, 50 µM D-2-amino-5-phosphonovalerate (APV) or 1 mM Mg2+ were added to the 
medium of both control neurons and 10 nM Aβ1-42- treated neurons at 4 DIV. Patch 
clamp recordings of sEPSC were done at 7 DIV. The regular extracellular solution was 
used to eliminate TTX, APV or Mg2+ from the culture, it was subsequently used with 
the addition of Gabazine to record sEPSC. 
 
 40 
Cell viability assay 
Neuronal viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide (MTT) assay  (Sigma Aldrich).  Cortical neurons were 
cultured in 12-well at the density of 75’000 cells/well and incubated at 1 DIV with 10, 
100 or 500 nM Aβ1-42. 4 DIV untreated and Aβ1-42-treated neurons were first washed 
with Phosphate Buffered Saline (PBS) 1x and then incubated with MTT 100 ng/ml 
(Sigma) dissolved in PBS 1x. The cells were then incubated for 90 minutes at 37°C. 
After MTT treatment, the supernatant was removed and the cells were lysed in 
DMSO. The absorbance was measured at 570 nm and 630 nm as a reference 
wavelengths (to measure cell debris) using Ultrospec 3000 (Pharmacia Biotech) 
spectrophotometer. All experiments were performed in duplicate. The cell viability of 
each treatment was expressed as percentage of the control. 
 
Transfection 
In order to obtain low-density fluorescent neurons for the analysis of the total 
dendritic length, neurons were transfected with an empty pLVTHM plasmid 
expressing EGFP using Lipofectamine 2000. To transfect 75’000 cells a mix of 1.5 µg 
DNA + 200 µl Neurobasal was prepared and vortexed. 3 µl Lipofectamine 2000 were 
added and the mix was stirred using vortex. After 15 minutes at room temperature, 
the mix was added to neuronal cultures and left for 45 minutes at 37°C. The culture 
medium was previously substituted with 1 ml fresh Neurobasal supplemented with 
conditioned medium (800 µl + 200 µl respectively). After 45 minutes, the entire 
medium was removed and 1 ml of conditionated medium was added to each well. 
Neurons were then kept at 37°C with 5% CO2. Cells was transfected at 3 DIV or 6 DIV 
then fixed at 4 DIV or 7 DIV respectively to make the total dendritic length analysis. 
 
Immunocytochemistry 
4 DIV and 7 DIV neurons were fixed with 2% paraformaldehyde plus 2% sucrose at 
room temperature for 8 minutes and washed in PBS three times. Then, samples were 
mounted on glass slides with Mowiol. Slides were observed under LSM510 META 
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confocal microscope (Carl Zeiss) using a x40 objective. Samples were excited at 488 
nm and recorded at 515-550 nm wavelengths. Images were elaborated with Zeiss 
LSM 510 Image Examiner software. Dendritic length was measured by tracing 
dendrites from the soma center, which was set at zero. Sholl analysis was made to 
measure the total dendritic length for each neuron. Series of circles with increasing 
gradii centered at the soma were generated and the length of the dendrites within 
each subsequent radial bin at 10 µm increments was summed. The dendritic length 
analysis was performed using NeuronStudio (CNIC) software.  
 
 
Western Blotting 
Cells samples (12-well) at 7 DIV were lysed in ice-cold RIPA buffer (NaCl 150 mM, 
Tris 50 mM, EDTA 1 mM, NP40 1%, Triton 1%) plus protease inhibitors cocktail. 
After gently shake for 20 min at 4°C, samples were centrifuged at 13000 g for 2 min 
(RT). Lysates were kept at – 80°C until use.  Protein concentration was assessed by 
Pierce BCA protein assay kit (Thermo Fisher). Complete lysis of the cells was 
obtained by 30 minutes of incubation in Lysis Buffer at 60°C. The same amount of 
proteins for each sample was loaded onto a 10% SDS-polyacrylamide gel 
electrophoresis (PAGE) under reducing conditions; resolved proteins were 
transferred onto Nitrocellulose membranes (GE Healthcare) of 0,2 µm pore size into 
a transfer buffer (glycin 1%, tris-base 0,02 M, methanol 20%) to which is applied a 
constant voltage.  
Membranes were first incubated for 1 hour at RT with 5% milk in PBS-0,02% Tween 
(TBST) on the oscillator to block non-specific binding sites. Subsequently, proteins of 
interested were probed with the primary antibody (diluted in TBST) for 1 hour at RT 
and revealed by secondary antibody conjugated with infrared-emitting fluorophores. 
Signals were detected and quantified using an Odissey scanner (Li-Cor) controlled by 
the ImageStudio software (Li-Cor). 
The primary antibodies used were: Spectrin, 1:500, α-rabbit (Cell Signaling), 
GAPDH, 1:10000, α-mouse (GeneTex Inc.). The secondary antibody used was α-
rabbit and α-mouse Li-cor Odissey 1:7500.  
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Analysis 
Data are reported as mean ± S.E.M (Standard error of the mean). Significance was 
taken at p<0.05 using unpaired two-tailed Student’s t-test, one-way ANOVA, two-
way ANOVA. Data for the total dendritic length (Fig.8; Fig.14) and sEPSC parameters 
comparison (Fig. 13; 16) were evaluated by two-way ANOVA (factors: DIV x Aβ1-42 
treatment for Fig.8; TTX x Aβ1-42 treatment for Fig. 14 and 13; NMDA-deprived 
condition x Aβ1-42 treatment for Fig.16). Cumulative probability distribution of sEPSC 
was tested for significance with a two-tailed Kolmogorov-Smirnov test and 
significance was defined as p<0.0001. Statistical analysis was performed using 
PRISM 4.0 software (Graph-Pad San Diego, USA).  
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Results 
 
Accumulation of Aβ in the brain as soluble and insoluble aggregates is central to the 
pathogenesis of AD [33]. For this reason, most of the studies have mostly analyzed 
the pathological outcomes triggered by Aβ on neuronal transmission and synaptic 
plasticity. To date, little is known about the physiological role(s) of monomeric Aβ; 
however, emerging evidences have reported an activity-dependent production of Aβ 
[160] strongly supporting a biological function of the peptide [176]. The main 
purpose of my research thesis is to explore the effects induced by monomeric Aβ, in 
its physiological form and concentration, on neuronal excitability. 
 
Aβ1-42 Depsi-Peptide assembly under culturing conditions 
As previously described, Aβ is found in human and murine brains (both healthy and 
AD suffering) at low concentrations ranging from picomolar to nanomolar [111], 
[112], [113], [177]. Due to the instability of its “intrinsically unfolded” structure, the 
monomeric form of Aβ tends to aggregate at high temperatures in a concentration-
dependent manner [178]. Thus, the main problem using synthetic amyloids is to 
control the conformational state of the peptide during the study. In our 
investigations, we used the Aβ1-42 Depsi-peptide which is a synthetic peptide designed 
to obtain pure solutions of monomers, in their native structure, or oligomers. After 
switching the pH of the buffer where the peptide is suspended, it is possible to choose 
the conformational state of Aβ by setting its incubation time (see methods). The 
suspension buffer of Aβ1-42-Despsi peptide is distilled water subsequently diluted in 
PBS 1X solution, thereby avoiding possible toxic effects on neuronal properties 
caused by others commonly used solvents such as DMSO. Furthermore, the low 
propensity to aggregate due to its high solubility [179], make the Aβ1-42 Depsi-peptide 
an ideal tool to study the monomeric form of Aβ. We are currently running 
experiments to test the conformational state of our Aβ1-42 Depsi-peptide monomeric 
preparation by Surface Plasmon Resonance (SPR) experiments. Increasing 
concentrations of monomeric Aβ1-42 Depsi-peptide (10 – 100 – 500 nM) were 
incubated for 72 hours at 37°C, the proper growth temperature for cells, and SPR 
analysis was made on these samples. Preliminary experiments suggested that 
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monomeric amyloid solution, diluted in Neurobasal medium, does not aggregate after 
72 hours of incubation at 37°C (data not shown). Using the Atomic Force Microscopy 
technique, we are planning to assess more accurately if there is a population of 
oligomers in our solution that cannot be detected by SPR. 
 
Monomers of Aβ1-42 Depsi-petide are not toxic for primary cortical neurons  
Aβ production and accumulation is mostly restricted in the “default-mode network”, 
a set of highly active brain regions that also include several cortical areas. As model 
system we therefore used cortical neurons from 18 days rat embryos. We tested the 
monomeric preparation of Aβ 1-42 Depsi-petide on neurons at 4 DIV, a very early 
stage of neuronal maturation. These cells have not yet formed an interconnected 
network and display immature electrical properties. Moreover, no signs of 
neuritogenesis or neuritic spines are evident at this stage of maturation as previously 
demonstrated [180]. Thus, 4 DIV neurons are a suitable model to examine a direct 
effect of the monomeric solution of Aβ1-42 Depsi-petide (AβM) on the electrical 
properties of isolate neuronal cells. The levels of monomeric Aβ are dynamically 
regulated by spontaneous activity, varying along brain areas [160]. Since Aβ 
aggregation is a concentration-dependent process and oligomers have been reported 
to be toxic for neurons [97]–[99], [181], the effects elicited by the Aβ peptide are 
Figure 1 - Slight alteration of neuronal viability following AβM treatment at 4 DIV  
Rat cortical neurons were incubated with 10 nM, 100 nM and 500 nM of AβM for 72 hours. Monomeric 
Aβ was added to the medium at 1 DIV. After 72 hours, cell viability tends to increase in neurons 
incubated with 10 nM AβM. Data are expressed in percentage of control and represent the mean 
percentage of basal viability ± standard error of three independent experiments, with duplicate 
samples. AβM 10 nM 106.6 ± 3.79; Aβ 100 nM 92.76 ± 2.38; AβM 500 nM 89.71 ± 6.75. *P<0.05 one-
way ANOVA (F(3,8)=3.504, p=0.0693 followed by Fisher’s post hoc test (10 nM vs 100 nM P=0.0418, 
10 nM vs 500 nM P= 0.0184) 
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therefore dependent on its amount in the brain ISF. We therefore decided to test 
different concentrations of the peptide based on previous in vitro studies on brain 
slices and dissociated cells in which Aβ level ranges from pM to µM concentrations. 
In our experiments, the lowest AβM concentration used was 10 nM, a value close to 
that measured in normal and AD-affected brains [111], [112], [113], [177] whereas the 
highest concentration used was 500 nM that resemble the Aβ concentrations 
commonly used in most of the scientific works focused on AD. To assess whether the 
AβM solution was neurotoxic, we first treated 4 DIV neurons with serial dilutions of 
AβM (10, 100, 500 nM) for 72 hours and determined the cell viability by MTT assay 
(Fig.1). Treatment with the lowest AβM concentration tested, 10 nM, has slightly 
increased cell viability compared to control group and it is significantly different from 
the viability of cells treated with highest concentrations of AβM (*P<0.05, One-way 
ANOVA). Consistent with previously finding [182], no significant toxic effect on 
neuronal viability was seen in neurons treated with both 100 nM and 500 nM AβM 
(Fig. 1).  
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Concentration-dependent effects of AβM on neuronal excitability of 4 DIV 
immature neurons 
Next, we monitored the neuronal excitability of 4 DIV control and AβM -treated cells 
by whole-cell patch-clamp recordings. To measure the firing rate, the resting 
membrane potential of the cells were held (Vh) at -60 mV and increasing pulses of 
depolarizing current (from 10 to 100 pA, 800 ms duration) were delivered. This 
protocol allow us to elicit the first action potential (AP) as well as the maximal activity 
achievable by the cells. Fig. 2A shows the electrical activity achievable by example 
Figure 2 - AβM alters the electrical activity of primary cortical neurons at 4 DIV 
The electrical activity of 4 DIV untreated and AβM-treated neurons was monitored by whole-cell 
patch-clamp technique in current-clamp mode. A. Representative traces recorded from 4 DIV 
untreated and AβM-(10 nM, 100 nM, 500 nM) treated neurons showing their evoked firing activity in 
response to 60 pA current injection. Dashed lines represent 0 mV B. Firing frequency as a function 
of injected current in untreated cells (white) and neurons treated with increasing concentrations of 
AβM (10 nM black; 100 nM dark grey, 500 nM light grey). *P<0.05 vs Ctrl #P<0.05 vs 10 nM; 
unpaired t-test for the individual steps of current. C. Rheobase values are significantly lower in 
neurons treated with 10 nM AβM compared to those treated with 100 nM and 500 nM AβM as well 
as to untreated neurons (*P<0.05 vs Ctrl; #P<0.05 vs 10 nM unpaired t-test) 
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cells from the four groups analyzed at 60 pA of current injection. Control cells at 4 
DIV were limited in their ability to generate APs displaying an immature firing 
pattern with a low frequency. Conversely, cells treated with 10 nM AβM fire much 
more rapidly compared to untreated neurons. However, treatment with 500 nM AβM 
did not increase the excitability of the cells, which display instead an electrical 
behavior comparable to that of control neurons. Treatment with 100 nM AβM has 
raised the firing frequency compared to control values but the effect was less 
pronounced than in neurons treated with 10 nM AβM. Despite the Rm was equal in all 
groups analyzed (see Table 1), we observe that the rheobase value, which is the 
minimum current for infinite duration at which the cell generates an AP,  was 
significantly lower in neurons treated with 10 nM AβM compared to untreated cells 
(*p<0.05) (Fig. 2C). In fact, the current that must be injected to the cells in order to 
generate the first AP increases with increasing concentration of AβM (Fig.2B). This 
result suggests that 72 hours treatment with 10 nM AβM makes neurons more 
excitable than both control cells and neurons cultured with higher concentrations of 
AβM peptide. Indeed, during step depolarizations (Fig. 2B), the firing frequency of 10 
nM AβM-treated neurons increased markedly relative to the firing rest of control cells, 
but only at current values near to the rheobase (from 40 to 60 pA) (Fig.2B). The 
firing frequency of the  
four groups was identical up to 30 pA and started to increase in 10 nM AβM-treated 
neurons above 40 pA. At 60 pA, untreated cells (n=11) had a mean maximal 
frequency of 3.18 ± 1.23 Hz compared to 10.62 ± 2.83 Hz in neurons cultured with 10 
nM AβM (n=12)  (*P<0.05 vs Ctrl). As suggested by rheobase values, there is an 
inverse correlation between AβM concentration and excitability. The firing frequency 
reached maximal values (from 8 to ~10 Hz) in 10 nM AβM-treated neurons and 
decreased when neurons were cultured with higher concentrations of the Aβ peptide. 
At 60 pA, the firing frequency varies between 5.53 ± 1.65 Hz in 100 nM AβM neurons 
and 1.53 ± 0.651 Hz in 500 nM AβM neurons (#p<0.05 vs 10 nM AβM), which is very 
close to the basal frequency of 4 DIV control neurons (3.18 ± 1.23 Hz) (Fig. 2B). By 
analyzing the cells able to generate a burst of APs, we observed an increase in the 
number of spiking neurons treated with both 10 nM and 100 nM AβM with respect to 
control cells and this phenomenon did not occur at 500 nM AβM (Percentage of 
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spiking neurons: Control cells 25% n=24; treated with (AβM) 10 nM 55% n=20, 100 
nM 53% n=17, 500 nM 22% n=9, data not shown).  
 
 
AβM treatment of immature cortical neurons results in the reduction of 
the AP width. 
The increased excitability of cortical or hippocampal circuits of Aβ overexpressing 
mice is a well reported phenomenon [127], [134], [131], [126]. These studies has been 
carried out on brain slices of young (from 5–7 [127] weeks old to 8–9 month old mice 
[131]) or adult (20–23 month old [126], [134]) transgenic mice in order to explore 
possible alterations in the intrinsic excitability properties.  However, in rodent, an 
overall maturation of the brain structures and synaptic density is completely achieved 
at the end of the first month after birth (for review [183]). The increase in the firing 
activity observed in Aβ overexpressing mice [127], [131], [132] points towards 
hyperexcitability and correlates with the high incidence of seizures in AD sufferers 
Figure 3 - AβM alters AP waveform in 4 DIV neurons 
A. The width of the first AP elicited with 80 pA current injections was measured in 4 DIV untreated 
and treated neurons with 10, 100, 500 nM AβM. The plot shows a direct correlation between AP 
width and AβM concentration. Control 10.8 ± 1.03 ms n=17; 10 nM AβM 6.6 ± 0.84 ms n=10; 100 nM 
AβM 8.8 ± 1.6 ms n=7; 500 nM AβM 12.3 ± 1.7 n=10 *p<0.05; one-way ANOVA followed by Fisher 
post hoc test. Circles indicate average values of AP width, bars indicate SEM B. AP amplitude was 
measured from the Vh to the peak of the AP, no significant differences were observed between the 
four conditions. C. Mean values of the spike threshold measured in the phase/plot. Values were 
taken as when dV/dt surpassed 5 mV/ms.  
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[122], [184]. Conversely, the cortical neurons used in our experiment were obtained 
from rat embryos at E18, a stage of development in which the membrane properties 
are still immature [185]; in fact the cells begin to mature electrically in the very early 
postnatal period instead embryonically [183]. Thus, the increased firing activity 
resulting in 10 nM AβM treatment might be an early sign of the electrical maturation 
of the neurons. To better explore how the electrical properties of the cells were 
altered, we analyzed some basic characteristics (duration, amplitude and threshold) 
of the first AP generated in response to 80 pA of current injection (Table 1). As shown 
in  Fig. 3A, cells cultured with 10 nM AβM showed narrower APs with decreased width 
values relative to control cell. On the contrary, higher concentrations of the peptide 
(100 nM, 500 nM) did not significantly reduce the AP duration compared to that 
recorded in untreated neurons (Fig.3A). The amplitude of the first AP was also  
measured. As shown in Fig.3B, the mean AP amplitude was between 80 and 95 mV in 
all groups and did not show any changes after AβM treatment at different 
concentrations (10, 100, 500 nM). There was also no significant difference in AP 
threshold between untreated cells and neurons treated with increasing 
concentrations of AβM (Fig.3c). In addition, changes induced by AβM on neuronal 
excitability were not associated with modification of the resting membrane potential 
(RMP), which was unaffected in all the conditions analyzed (Table 1). 
 
 
 
 
Table 1 - Summary of RMPs and AP parameters measured in untreated and  AβM-treated neurons at 4DIV 
 Ctrl 10 nM  AβM 100 nM  AβM 500 nM  AβM F P value 
RMP (mV) - 60.57 ± 1.06 
n= 23 
- 63.2 ± 0.98 
n= 19 
- 60.2 ± 1.04 
n= 9 
- 63.67 ± 1 
n= 9 
(3,56) 
2.25 
0.092 
AP width (ms) 10.81 ± 1.03 
n= 10 
6.66 ± 20.84 
n= 17 
8.78 ± 1.58 
n= 7 
12.32 ± 1.76 
n= 10 
(3,40) 
4.65 
0.007 
Amplitude (pA) 94.19 ± 4.12 
n= 7 
92.82 ± 4.72 
n= 7 
96.21 ± 5.14 
n= 7 
82.83 ± 3.15 
n= 5 
(3,22) 
1.44 
0.257 
Treshold (mV) - 18.79 ± 3.82 
n= 7 
- 21.87 ± 1.36 
n= 7 
- 21.06 ± 2.68 
n= 7 
- 19.6 ± 0.86 
n= 5 
(3,22) 
0.29 
0.833 
RMP and AP parameters were calculated for untreated and neurons treated with 10 nM AβM, 100 nM 
AβM, 500 nM AβM at 4 DIV. Values are expressed as mean ± SEM. *p<0.05, one-way ANOVA 
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Firing pattern maturation of 4 DIV neurons treated with 10 nM AβM 
 We observed a concentration-dependent effect induced by AβM treatment on 
neuronal excitability of immature neurons at 4 DIV (Fig.2). Neurons cultured with 
500 nM AβM displayed a discharged firing pattern that was very similar to that 
recorded in 4 DIV control neurons. This is possibly due to an early aggregation of 
AβM in oligomers that are known to impair neuronal functioning [97]. Conversely, the 
chronic presence of 10 nM AβM for 72 hours is able to elevate the neuronal firing 
frequency (Fig.2B) by reducing the duration (Fig.3A) of individual APs. These 
changes in the electrical activity induced by 10 nM AβM recapitulate a physiological 
process of electrical maturation typical of neuronal cells [185]. Moreover, the viability 
of treated neurons was not affected by 10 nM AβM treatment, which instead caused a 
slight increase in the cell metabolism (Fig. 1). Our final goal has been to elucidate a 
potential physiological role of AβM by using a concentration as close as possible to 
those found in both normal and AD brains, which range between pM to nM 
concentrations [111], [113], [108], [177]. Among the overall concentrations we tested, 
10 nM AβM was the minimum amount with the clearest biological effect on neurons. 
Therefore we only focused on this concentration for the subsequent experiments.  
Neurons cultured with 10 nM AβM for 72 hours showed a firing frequency as well as 
some APs duration similar to those commonly found in cells at more mature stages of 
development. Over time, developing neurons spontaneously display an increment in 
the firing rate that stabilizes at mature age (Fig.4A) [186]. Accordingly, we used the 
duration of the first-elicited action potential as a parameter to compare the electrical 
activity of both 4 DIV untreated and 10 nM AβM-treated cells to that assessed at 
higher in vitro stages of maturation, such as 11 DIV and 18 DIV (Fig.4B). Neurons 
cultured with 10 nM AβM showed an AP width lower than immature 4 DIV but still 
higher than 11 DIV and 18 DIV control neurons suggesting a possible implication of 
AβM in neuronal electrical maturation (Fig. 4B) 
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Analysis of ionic conductances on 10 nM AβM -treated cells at 4 DIV 
Any modifications in passive properties of neurons could lead to an alteration in the 
electrical activity of excitable cells, thus we analyzed these biophysical parameters in 
both untreated and 10 nM AβM-treated neurons. As summarized in Table 2, RMP, 
input resistance (Rin) and membrane capacitance (Cm) were comparable in the two 
conditions analyzed (Table 2).  
 
Figure 4 - Treatment with 10 nM AβM induces electrical changes toward an advanced stage of 
maturation. 
A. Representative recordings of neurons at different stages of maturation and in 4 DIV treated with 
10 nM AβM. Current clamp recordings of firing activity elicited by a current step of 55 pA, 800 ms 
duration. Dashed lines represent 0 mV B. AP width values were plotted for all the conditions 
analyzed (4 DIV untreated, 4 DIV 10 nM AβM, 11 DIV untreated, 18 DIV untreated). 4 DIV untreated 
10.8 ± 1.04 ms n=10; 4 DIV 10 nM AβM 6.65 ± 0.84 ms n=17; 11 DIV untreated 2,91 ± 0.17 ms n=7; 
18 DIV untreated 2.4 ± 0.05 ms n=4  *p<0.05; one-way ANOVA followed by Fisher post hoc test.  
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We then analyzed the ionic conductances mainly involved in the generation of AP. We 
firstly measured the voltage-dependent sodium currents (INa) of both untreated and 
10 nM AβM-treated neurons. A voltage step protocol (from – 80 to +60 mV, 20 mV 
increment, 800 ms duration) was applied to single voltage clamped neuron. After 
recording of stable whole-cell current, the protocol was then repeated after bath-
applied 300 nM TTX to isolate INa. Pure TTX-sensitive current was obtained 
subtracting the membrane current left after the selective block of INa from whole cell 
current. As shown in Fig 5, the average amplitude of the inward INa was unchanged 
in 10 nM AβM treated-neurons compared to untreated cells. Furthermore, the 
involvement of INa to spike generation was also derived by the phase plot (obtained 
by drawing the first time derivative of voltage (dV/dt) vs. voltage) analysis of the 
spike threshold potentials. The threshold values were comparable between the two 
groups (control -23.2 ± 0.97 pA; 10 nM AβM -21.01 ± 1.6 pA, unpaired t-test *p < 
0.05). We therefore conclude that the Na+ channels responsible for AP generation  
Table 2 -  Summary of passive properties of untreated and  10 nM AβM-treated neurons at 4 DIV 
 Ctrl 10 nM  AβM P value 
RMP (mV) -60.57 ± 1.06 
n= 23 
-63.21 ± 0.98 
n= 19 
0.079 
R
in
 (MΩ) 1454 ± 299 
n=11 
1192 ± 126 
n= 10 
0.445 
Cm (pF) 19.55 ± 2 
n= 11 
23.64 ± 1.9 
n= 10 
0.153 
Passive properties calculated for untreated and 10 nM AβM - treated neurons at 4 DIV. Values are 
expressed as mean ± SEM. *p<0.05, unpaired t-test. 
Figure 5 - Sodium current is not altered 
following 10 nM AβM treatment 
Current-voltage relationship plot of INa 
recorded in 4 DIV untreated (blank 
circles) and 10 nM AβM treated neurons 
(black circles). INa was normalized on cell 
capacitance.  
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are not the main causes of the different firing pattern observed in AβM treated-
neurons. 
If INa regulate the rising phase of APs, then potassium currents (IK) are responsible 
for the repolarization of the membrane potential. The delayed rectifier K-current 
(IKV) and A-type current (IKA) are two of the potassium currents that mainly 
compose the total outward current of cortical neurons and also contribute to spike 
repolarization [187],  [188]. We therefore measured these outward currents in 
neurons at 4 DIV. IKV is mainly sensitive to Tetraethylammonium (TEA) and slowly 
inactivating, whereas IKA is fast inactivating and mainly sensitive to 4-aminopyridine 
(4-AP). These two types of potassium current are usually pharmacologically isolated 
from the total whole cell current. However, both IKV and IKA are sensitive to both 
TEA and 4-AP making their separation from the total outward current not accurate, 
Figure 6 - Slight alterations of IKV and IKA induced by 10 nM AβM 
 A. Graphical representation of the protocol used to obtain IKV and IKA. Briefly (a) The total outward 
current (which is composed by IKA and IKV) was recorded by a voltage step from  -80 mV to -5 mV. 
(b) IKV was evoked by a voltage step from – 40 mV to -5 mV. (c) IKA was isolated by analytical 
subtraction of IKV from the total potassium current (a) (IKA + IKV) recorded in the same cell. 
Currents were normalized on cell capacitance B. At the bottom, the plot represents the values of 
IKA density of untreated cells (white, untreated neurons 351.2 ± 58.14 pA n=19) and 10 nM AβM 
treated neurons (black, 211.8 ± 18.52 pA n=24) (t-test, *p<0.05). At the top, representative IKA 
patch-clamp recording of untreated cells (grey) and AβM treated neurons (black). C. At the bottom, 
the plot represents the values of IKv density of untreated cells (white, untreated 103.2 ± 13.85 pA 
n=24) and 10 nM AβM (black, 70.13 ± 7.39 pA n=21) (student t-test, *p<0.05). At the top, 
representative IKA patch-clamp recording of untreated cells (grey) and AβM treated neurons (black). 
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even at low concentration of the blockers [189]. Thus, we isolated IKV and IKA by 
applying a voltage-step protocol from two different holding potentials (-80 mV or -40 
mV) to – 5 mV (2000 ms duration) (Fig. 6A). The current recorded by holding the 
cells at -80 mV is mainly composed by both IKV and IKA (Fig.6Aa), whereas the 
inactivation of the A-type potassium channels at -40 mV allows the isolation of IKV 
(Fig.6Ab). Thus, IKA was obtained by analytically subtracting the IKV from the total 
outward current (IKV + IKA) recorded [189] (Fig. 6Ac). IKA significantly decreased 
from 351.2 ± 58.14 pA (n=19) in control cells to 211.8 ± 18.52 pA (n=24) (* p<0.05, 
unpaired t-test) in AβM-treated cells (Fig. 6B). The slowly inactivating K-current - IKV 
- has slightly, but significantly, decreased in neurons treated with 10 nM AβM (control 
103.2 ± 13.85 pA n=24; 10 nM AβM 70.13 ± 7.399 pA n=21) (* p<0.05, unpaired t-
test) (Fig. 6C). A reduction in the outward current could be implicated in the 
increased excitability displayed by neurons cultured with 10 nM AβM. However, we do 
not know whether the decrease in IKV and IKA is due to a decrease in the number of 
active channels or to modifications in their properties.  
 
Effects of 10 nM AβM treatment on the total dendritic length in 4 DIV neurons 
We found that 10 nM AβM - treatment alters the waveform of the first AP decreasing 
its duration (Fig. 3). These alterations are likely due to a decrease in the outward 
currents of the cells (Fig. 6), both IKV and IKA. The final effect was an increase in the 
rate of the firing pattern displayed by immature neurons that resembles the spiking 
activity of cells at more mature stage of development (Fig. 4A). 
In developing neurons excitability goes with the spreading of the dendritic processes 
that are prompted to growth by the afferent electrical activity [190]. Thus, the total 
dendritic length of 4 DIV control cells was compared to that measured in 10 nM AβM - 
treated neurons (Fig.8). As the excitability increased, even the total dendritic length 
raised by 20% increment in cells exposed to 10 nM AβM relative to control neurons 
(Fig. 7). 
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Since modifications in cell morphology correlate well with functional synaptogenesis, 
we next wondered whether synaptic currents of immature neurons were affected by 
treatment with 10 nM AβM. However, neurons at 4 DIV display undeveloped synapses 
which spontaneous activity is awkward to record and analyze; synaptic currents are 
thus undetectable in most of the cells. For this reason, we still used immature 
neurons though at a more advanced stage of in vitro development. We shifted the 
experimental window forward, keeping the duration of the treatment unchanged: 4 
DIV neurons were cultured with 10 nM AβM for 72 hours and the experiments were 
performed at 7 DIV. We therefore wanted to reproduce the results obtained in 4 DIV 
immature neurons also in 7 DIV cells. That is, we observed whether AβM-treated 
neurons at 7 DIV displayed an augmented dendritic arborization and an increased 
excitability as seen at 4 DIV. Thus, before studying the effects of 10 nM AβM on 7 DIV 
synaptic activity, we did an immunocytochemistry analysis to measure the total 
dendritic length of 7 DIV control and 10 nM AβM-treated neurons. 
Figure 7 - The dendritic arbor growth increases after treatment with 10 nM AβM in 4 DIV 
neurons. 
Analysis of total dendritic length in 4 DIV untreated and 10 nM AβM-treated neurons. Neurons were 
treated at 1 DIV, transfected with GFP at 3 DIV and fixed at 4 DIV. Images were acquired at the 
confocal microscope, from 3 different culture preparations, minimum 5 cells for each conditions were 
analyzed. A. Representative images of control cells and 10 nM AβM-treated neurons at 4 DIV. Scale 
bar= 20 µm B. Treatment with 10 nM AβM results in a significant increase in the average length of 
dendrites (Control 520.5 ± 37.62 µm n=26; 10 nM AβM  676.3 ± 48.32 µm n=23) (unpaired t-test, 
*p<0.05). 
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Figure 8 - Treatment with 10 nM AβM causes the growth of the dendritic arbor in immature 
neurons at 4 DIV as well as 7 DIV. 
Cells were treated at 4 DIV, transfected with GFP at 6 DIV and fixed at 7 DIV. Images were 
acquired at the confocal microscope, from 2 different culture preparations. Minimum 5 cells for 
each conditions were analyzed A. Representative images of control cells and 10 nM AβM-
treated neurons at 7 DIV. Scale bar= 20 µm B. The total dendritic length of 4 DIV neurons were 
compared to that measured in 7 DIV neurons in normal condition or after treatment with AβM. (4 
DIV Control 520.5 ± 37.62 µm ; 10 nM AβM  676.3 ± 48.32 µm; 7 DIV Control 823 ± 78.8 µm; 10 
nM AβM  1040 ± 96.1 µm, two-way ANOVA followed by Tukes post hoc test, *p<0.05) 
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Low concentrations of AβM, 10 nM, caused an increase in the total length of the 
dendritic arbor by about 20% compared to control condition. The increment of the 
dendritic arbor growth in AβM-treated cells is not statistically significant compared to 
control neurons (note that only 2 culture preparations were analyzed), but it 
maintains the same trend obtained at 4 DIV (Fig.8). Since the main effect of 10 nM 
AβM was to increase the excitability of 4 DIV silent cells (Fig.2), we also stimulated 7 
DIV neurons with increasing current injections to assess any modification in the 
electrical behavior after treatment with 10 nM AβM. Whole-cell patch-clamp 
experiments in current clamp mode were carried out on control and treated-cells. As 
shown in Fig. 9, at the same value of current injection, treated neurons elicit a train of 
APs at higher frequency than control cells, 
thus appearing more excitable. To confirm 
this idea, we looked at the rheobase values, 
that represent a measurement of neuronal 
excitability. The rheobase values decreased 
from 54.66 ± 6.819 pA (n=13) for control cells 
to 37.40 ± 4.309 pA (n=12) for 10 nM AβM-
treated neurons (*P<0.05, unpaired t-test) 
(Fig.10A). Note that, as shown in Fig. 10B, 
around the threshold level (40 pA) of current 
injection, 7 DIV treated cells triggered APs 
firing at lower injected current than control 
neurons whereas both conditions reach the 
firing-saturation at high current values.  
In addition, values reported in table 2 show 
that the passive properties of 7 DIV control 
cells and those exposed to 10 nM AβM are 
comparable. 
 
 
 
Figure 9 - Electrical activity of 7 DIV 
neurons treated with 10 nM AβM 
Representative traces of 7 DIV untreated 
and 10 nM AβM -treated neurons recorded 
in current clamp mode. The electrical 
activity of neurons is elicited by a 55 pA 
current step, lasting 800 ms duration. The 
treatment with 10 nM AβM increases the 
firing activity of immature neurons.
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Synaptic activity modifications in 10 nM AβM - treated cells at 7 DIV 
We observed that both electrical activity and morphology of immature neurons were 
affected by a chronic treatment (72 hours) with 10 nM AβM and this effect is 
reproducible in both 4 DIV and 7 DIV developing neurons (Fig. 2, 8, 10).  
We were therefore able to determine whether the synaptic activity was also affected 
by chronic exposure to 10 nM AβM. We firstly recorded spontaneous excitatory 
postsynaptic currents (sEPSC) by blocking GABA-inhibitory synaptic transmission (5 
µM Gabazine) and maintaining the spike-mediated release. sEPSC were not 
detectable in some cells confirming that neurons at 7 DIV were still integrating into 
the network. Changes in sEPSC properties (such as frequency, amplitude, rise and 
decay times) reflect modifications in either post- or pre-synapses. In particular, any 
modification in the amplitude of EPSC is related to both different postsynaptic 
density receptors and amount of release neurotransmitter in functional synapses 
whereas EPSC frequency is dependent upon pre-synaptic vesicular release probability 
and number of functional synapses. The area of sEPSC is related to the total charge 
carried by the synaptic events, whereas their kinetic features are represented by the 
rise and decay time. Any alterations in these parameters suggest the presence of a 
different receptor subunit population at the post-synapses. 
Table 3 - Passive properties of untreated and 10 nM AβM-treated neurons at 7 DIV 
 Ctrl 10 nM  AβM P value 
RMP (mV) -59.9 ± 2.1 
n= 8 
-63.4 ± 1.93 
n= 8 
0.241 
Rin (MΩ) 896 ± 137 
n=8 
877 ± 116 
n= 8 
0.916 
Cm (pF) 33.8 ± 2.32 
n= 8 
37.3 ± 3.57 
n= 8 
0.426 
Passive properties calculated for untreated and 10 nM AβM - treated neurons at 7 DIV. Values are 
expressed as mean ± SEM. *p<0.05, unpaired t-test. 
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We therefore analyzed frequency, amplitude, area as well as rise and decay time of 
sEPSC comparing the values obtained in control and treated-neurons. As shown in 
Fig.11A (inset), the average sEPSC amplitude was significantly increased after 72 
hours 10 nM AβM treatment, as denoted by the rightward shift of the cumulative 
probability distribution (Fig. 11A main panel). In addition, the size of the synapses 
remains unchanged after treatment with 10 nM AβM as shown by the presence of only 
one population of sEPSC, with the amplitude values ranging from 10 to 20 pA, in the 
cumulative probability distribution.  
Figure 10 - 7 DIV neurons treated with 10 nM AβM show increased excitability 
A. The reduced rheobase values of 10 nM AβM-treated neurons show that less current is needed 
to elicit an AP with respect of control neurons (untreated 54.66 ± 6.819 pA n=13; 10 nM AβM 37.40 
± 4.309 pA n=12, *p<0.05 unpaired t-test ). B. The number of spikes generated by a step of 
current is plotted against the amount of current injected at each step. 10 nM AβM - treated (black) 
neurons reach their maximum firing rate when about 50 pA of current are injected, a condition that 
fails to induce any electrical response in untreated neurons (white) (*p<0.05, unpaired t-test) 
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Also the frequency of the events was increased by 3-fold in treated neurons compared 
to control cells, as illustrated in Fig. 11B. Conversely, none of the conditions 
considered exhibited significant changes in rise time and decay time (Fig. 11C). 
Furthermore, the sEPSC area was not affected in 7 DIV 10 nM AβM-treated cells 
(Table 4). 
Figure 11 - sEPSC parameters of control cells are altered after 10 nM AβM - treatment 
A. sEPSC were recorded at -70 mV in voltage-clamp mode. Gabazine (5 µM) was added to the 
external solution to block the GABA mediated transmission. On the left, the main plot represents the 
amplitude cumulative probability while the small plot represents the average values of sEPSC 
amplitudes of untreated (white) and treated neurons (black) (two-tailed Kolmogorov-Smirnov 
*p<0.0001). On the right, the representative traces of the average events recorded in one cell 
(untreated cells in grey, treated neurons in black). (Control cells 8.86 ± 0.58 pA n=18; 10 nM AβM 
cells 11.6 ± 0.65 pA n=18; unpaired t-test *p<0.05) B. On the left, the average values of the sEPSC 
frequency in untreated (white) and treated neurons (black). On the right, representative traces of 
sEPSC in untreated (grey) and treated neurons (black). Control 0.32 ± 0.04 Hz n=25; 10 nM AβM 
0.92 ± 0.13 Hz n=25; * p<0.05 unpaired t-test C. Rise and decay times were measured in untreated 
(white) and treated neurons (black). Rise time: Control 0.93 ± 0.06 ms n=25; 10 nM AβM 0.96 ± 0.06 
ms n=25; ; decay time: Control 7.94 ± 0.81 ms n=18; 10 nM AβM 7.67 ± 0.72 ms n=20; unpaired t-
test *p<0.05.  
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The sAMPA-response induced by chronic treatment with 10 nM AβM could be 
associated to excitotoxicity, which is a pathological process caused by an over-
activation of glutammatergic receptors, such as AMPA and NMDA receptors, leading 
to neuronal death [191]. To assess a possible glutamate-induced toxicity in cultures 
exposed to 10 nM AβM, we performed a preliminary WB analysis of spectrin protein 
(Fig. 12). Spectrin is a cytoskeleton-linked protein, which is cleaved during 
excitotoxicy processes [192], thus we analyzed the levels cleaved spectrin in untreated 
and AβM-treated cells. As shown in Fig.13, the ratio between cleaved and total 
spectrin did not change in the two conditions analyzed, suggesting that the overall 
effects on sEPSC induced by 10nM AβM treatment are not associated with increased 
vulnerability to excitotoxicity. 
 
AβM-induced electrical activity regulates synaptic strengthening and dendritic 
arborization 
Data reported in Fig.11 show that treatment with 10 nM AβM caused an increase in 
both sEPSC amplitude and frequency of developing neurons, thus an improvement in 
excitatory synaptic transmission. However any modifications in spontaneous EPSC, 
Figure 12 - Increased neuronal activity in 10 nM AβM-treated neurons is not associated with 
excitotoxicity. 
A. Western blotting for cleaved spectrin and total spectrin in lysates of neurons at 7 DIV, untreated 
and treated with 10 nM AβM. B. The plotted values represent the ratio between the levels of cleaved 
spectrin over total spectrin normalized for the control (untreated 1.0 ± 0.13; 10 nM AβM treated 0.89 ± 
0.07; one culture preparation) 
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, which are APs-driven events, are caused by alterations in the properties of pre- or 
post-synaptic cells and/or by modifications in the network activity. The presynaptic 
strengthening, seen as an increased sEPSC frequency in AβM-treated cells, is likely 
due to a rise in the number of spiking neurons and also to an enhanced firing activity 
of those cells. Further experiments on miniature EPSC (mEPSC) are therefore needed 
to elucidate the properties of synaptic currents generate by APs-independent release 
in both conditions. 
Figure 13 - The effects of 10 nM AβM on sEPSC is dependent on neuronal excitability 
Neurons were cultured in two conditions: TTX alone or TTX and 10 nM AβM at 4 DIV for 72 hours, 
sEPSC were recorded at 7 DIV. A. On the left average values of sEPSC frequency in control 
neurons (white circles, not treated with AβM) and 10 nM AβM treated neurons (black circles). On 
the right, representative traces of sEPSC in control (grey, TTX) and 10 nM AβM condition (black, 
TTX + 10 nM AβM) (Control 0.326 ± 0.04 pA; w/ TTX Control 0.34 ± 0.08 pA; 10 nM AβM 1.01 ± 
0.12 pA; w/ TTX 10 nM AβM 0.61 ± 0,14 pA; unpaired t-test *p<0.05) B. On the left average values 
of sEPSC amplitude in control neurons (white circles, not treated with AβM) and 10 nM AβM 
treated neurons (black circles). On the right, representative average sEPSC events recorded from 
one single cell in control (grey, TTX) and 10 nM AβM condition (black, TTX + 10 nM AβM) (Control 
8.58 ± 0.48 pA; w/ TTX Control 10 ± 0.9 pA; 10 nM AβM 11.2 ± 0.55 pA; w/ TTX 10 nM AβM 9.52 ± 
1.13 pA; unpaired t-test *p<0.05). NT=Not Treated 
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To assess whether the increase in the firing frequency occurs before the strengthening 
of synapses or vice versa, we chronically cultured cells with 10 nM AβM and 1 µM TTX 
(a sodium channel blocker) for 72 hours to inhibit the spontaneous electrical activity. 
We therefore recorded sEPSC by using the regular external solution, thus removing 
the TTX blocker. 
As shown before, both sEPSC amplitude and frequency were increased after 
treatment with 10 nM AβM w/o TTX applying (Fig. 13 A, B) However, control neurons 
showed a peculiar enhancement of sEPSC amplitude after the complete block of APs 
firing with TTX. This phenomenon is commonly known as “synaptic scaling”; it is a 
form of synaptic plasticity that allows neurons to sense the level of our own electrical 
activity in order to adjust and stabilize the firing by scaling up or down the strength of 
excitatory synapses and so maintain an homeostatic stability [193]. Basically, a 
neuron deprived of electrical activity - such as under TTX treatment – enhances the 
strength of excitatory synapses by improving the amplitude of EPSC and vice versa. 
Thus, the increased sEPSC amplitude displayed by control cells cultured with TTX is 
Figure 14 - The growth of dendritic processes is regulated by AβM-induced excitability 
A. Example images of 7 DIV untreated and 10 nM AβM treated neurons in control (- TTX) or activity-
deprived condition (+ TTX, 1 µM). Neurons were treated at 4 DIV, transfected with GFP at 6 DIV and 
fixed at 7 DIV. Images were acquired at the confocal microscope from 2 different culture 
preparations, minimum 5 cells were analyzed for each conditions B. Analysis of total dendritic length 
of control cells and treated neurons culture with or without TTX (Control 823 ± 78.8 µm; w/ TTX 
Control 681 ± 101 µm; 10 nM AβM 1040 ± 96.1 µm; w/ TTX 10 nM AβM 720 ± 106 µm). #p<0.05 vs10 
nM w/o TTX, two-way ANOVA followed by Fisher test 
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a common homeostatic regulation of excitatory neurons.  
Both sEPSC frequency and amplitude of 10 nM AβM –treated neurons has decreased 
close to control values (Fig. 13A,B) after 72 hours of in activity-deprived condition 
(Fig. 13B). Thus, the strengthening of excitatory synapses caused by 10 nM AβM 
seems to take place after the increase of firing activity which actually prompts the 
synaptic improvement probably due to a “synaptic scaling”-independent mechanism. 
We next measured the total dendritic length of activity-deprived neurons in control 
and 10 nM AβM-condition. Blocking the firing activity for 72 hours has significantly 
inhibited the length of the dendritic processes displayed by AβM-treated neurons (Fig. 
14B) (#P<0.05 Two-way ANOVA). Conversely, the dendritic trees growth of control 
neurons was weakly affected by TTX treatment (Fig. 14B).  This data is consistent 
with previous results that have shown a strong influence of neuronal activity on 
dendritic arborization [190], [194], [195]. 
Figure 15 - On the left, representative traces of sEPSC recordings of control (grey) and 10 nM 
AβM-treated neurons (black) cultured with APV or Mg2+ at 4 DIV for 72 hours. sEPSC were 
recorded at 7 DIV. APV was used at 50 µM whereas Mg2+  was used at 1 mM. On the right, 
representative spontaneous events recorded from control (grey) and 10 nM AβM treated neurons 
(grey) A. sEPSC frequency and amplitude increase after 10 nM AβM treatment B-C. The sEPSC 
frequency is altered after treatment with APV (B) or Mg2+ (C) but only in control neurons, whereas 
the amplitude remains unchanged in both untreated and treated cells.  
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Effects of NMDA receptors in AβM-induced outcomes on sEPSC 
The levels of glutamate ionotropic receptors, both NMDA and AMPA receptors, are 
finely regulated during neuronal development. At early stages of maturation, neurons 
displays “silent synapses” that lack of functionally AMPA receptors (AMPAR). Their 
sequential development and insertion into post-synaptic membranes – the so-called  
“AMPAfication” [196]– is a process mainly mediated by NMDA receptors (NMDAR). 
Thus, the synaptic strength improvement induced by low concentrations of AβM on 
immature neurons (Fig. 11) could be an NMDA-dependent process. For this reason, 
we blocked the NMDAR for 72 hours using 50 µM D-2-amino-5-phosphonovalerate 
Figure 16 - Analysis of sEPSC parameters in NMDA-deprived conditions 
Average values of sEPSC frequency (A), amplitude (B), area (C), rise and decay time (D) in 
control neurons (white circles, not treated with AβM) and 10 nM AβM treated neurons (black 
circles). * p<0.05 Ctrl vs 10 nM AβM; #P<0.05 NT vs APV or NT vs Mg 2+ for both control and AβM -
treated neurons, two-way ANOVA followed by Tukey’s post hoc test. 
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(APV) in culture medium and we subsequently recorded sEPSC in control cells and 
neurons treated with 10 nM AβM using the regular external solution thus washing 
away the NMDA-blocker. When NMDAR are chronically blocked both sEPSC 
frequency and amplitude were strongly affected in control cells (Fig 15B, 16A-B)  
 (#P<0.05 two-way ANOVA). Indeed, it was recorded a 3-fold increment of sEPSC 
frequency (Fig. 16A) and a 2-fold increase in the sEPSC amplitude of control neurons 
cultured with APV (Fig. 16B) (#P<0.05 two-way ANOVA). Conversely, 10 nM AβM-
treatment, in NMDAR-activity deprived condition, completely abolished the increase 
in sEPSC frequency and amplitude showed by APV-treated control cells (Fig. 15B). 
sEPSC frequency of AβM-treated neurons went back to control values (Fig. 16A) 
whereas the amplitude was unaffected compared to that of control cells exposed to 
APV (Fig.16B) (*P<0.05, two-way ANOVA). 
 Chronic inhibition of NMDAR activity caused an increase in both sEPSC amplitude 
and frequency in control cells; it is probably due to a compensatory mechanism of 
synapses to counteract the chronic block of the excitatory receptors. This is also 
supported by sEPSC recordings performed in control neurons chronically cultured 
with high concentrations of Mg2+ (1 mM added to the culture medium) that saturate 
NMDAR even at depolarized potential. Both pre- and post-synapses were found to be 
Table 4  
 NT APV Mg++ 
 
 
Ctrl AβM 10 nM Ctrl AβM 10 nM Ctrl AβM 10 nM 
Frequency 
(Hz) 
0.32 ± 0.04 1.01 ± 0.12 1.23 ± 0.26 0.51 ± 0.23 1.23 ± 0.26 0.356 ± 0.11 
Amplitude 
(pA) 
8.58 ± 0.48 11.2 ± 0.55 14.28 ± 2.25 13.0 ± 4.0 12.95 ± 1.74 12.38 ± 1.58 
Area 
(pA*ms) 
46.76 ± 4.94 53.08 ± 4.9 67.94 ± 4.95 67.53 ± 10.79 83.84 ± 
18.24 
46.29 ± 9.61 
Rise time 
(ms) 
 
0.9 ± 0.04 0.97 ± 0.06 0.84 ± 0.1 1.03 ± 0.15 0.84 ± 0.09 0.72 ± 0.06 
Decay time 
(ms) 
7.33 ± 0.63 7.54 ± 0.6 6.67 ±1.39 4.76 ± 0.65 7.43 ± 0.86 5.54 ± 0.88 
Average values of sEPSC parameters in control neurons and 10 nM AβM treated neurons when 
cultured in normal condition (NT), with APV or Mg 2+ for 72 hours. 
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potentiated with increased frequency and amplitude compared to control condition 
(Fig. 15C, 16A-B) (*P<0.05 two-way ANOVA). Cells treated with both 10 nM AβM and 
high Mg2+ for 3 days has maintained the same trend seen after the chronic block of 
NMDAR with APV: sEPSC frequency decreased at control values (*P<0.05 two-way 
ANOVA) while the amplitude was not affected compared to AβM-untreated neurons 
(Fig. 15C, 16A-B). Moreover, the area and the sEPSC kinetics parameters (rise and 
decay times) of the excitatory events were comparable in all groups (Fig. 16C) (Fig. 
16D). 
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Discussion 
 
So far, the Aβ peptide has been addressed as a pathological peptide, linked to AD 
development and progression. Thus, in the last 30 years, the scientific community 
has been focused on studying the multiple ways in which the peptide can exert its 
toxicity upon neurons and to find a way to eradicate Aβ from the brain of patients. 
Considered mainly an aberrant peptide or wasting product of cell metabolism, little 
research has ever been dedicated to the study of Aβ peptide possible role in 
physiological conditions. 
However, growing evidences are highlighting the biological function(s) of APP and its 
derivatives - including Aβ - as crucial factors in maintaining neuronal homeostasis 
[47]. Aβ is found at low concentrations (pM and nM) in both human and murine ISF 
collected from healthy and AD brains [111], [112], [113], [177]; furthermore the 
accumulation of the peptide in extracellular plaques, a well-known hallmark of the 
disease, has been shown to be asymptomatic in certain cases and not related to AD 
onset [93]. The failure of Aβ-centric treatments, that aim to remove or reduce the 
concentration of the Aβ peptide from brain compartments, is a further evidence of its 
relevance for the cerebral homeostasis (see chapter 4). An emerging physiological 
role of Aβ is sustained by recent results indicating that the peptide may work as a  
modulator of synaptic plasticity at low concentrations (pM). By acting directly at pre-
synapses [170] or indirectly on post-synaptic α7-nicotinic receptors (nAChRs) [197], 
[198], [199] it has been shown that Aβ positively regulates the synaptic transmission 
by enhancing both the presynaptic strength and LTP.  
Our work starts from these assumptions and gives more information about Aβ effects 
on neuronal activity. In particular, our data support the hypothesis that Aβ has a 
modulatory effect on neuronal synaptic transmission and also demonstrate that low 
concentrations (10 nM) of Aβ1-42 monomers (AβM) can enhance the electrical activity 
of immature cortical neurons. 
The in vitro maturation of neuronal cultures reaches its peak at 14 DIV at which 
neurons display enhanced connectivity and firing rate compared to younger neurons 
[200], [201]. For our experiments we used primary cultures of embryonic neurons at 
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4 DIV and 7 DIV in order to study the alterations induced by AβM on the neuronal 
activity of electrically silent or low-frequency firing cells. 
Our investigations are based on a chronic treatment (72 hours) with exogenous Aβ1-42 
monomers. The Aβ1-42 preparation used was synthetized through the solid phase 
protein synthesis (SPPS) which allows to obtain a pure solution of soluble monomers 
of Aβ1-42 in its native structure [179]. We used this solution at different 
concentrations (10 nM, 100 nM, 500 nM) to treat neurons and we found that AβM 
modifies the electrical behavior of the cells in a concentration-dependent manner. 
AβM 500 nM zeroed the effects caused by lower concentrations (10 nM) of AβM on 
neuronal excitability (Fig.2). High levels of monomeric Aβ have been reported to be 
deleterious (0.2 µM [202]), (1 µM [203]) prompting its oligomerization [204], a 
process known to be involved in AD progression. Indeed, in physiological conditions, 
the processes of production and clearance of Aβ are finely regulated to avoid 
undesired accumulations of the peptide and subsequent aggregation, since 
oligomerization is likely to occur whenever the peptide is present in a solution at 37°C 
and pH 7.4, as the physiological brain environment [205]. Thus the overall 
concentration of Aβ in the extracellular space of healthy brain is maintained in the 
range of picomolarity and nanomolarity [111]. 
Our data show that 10 nM AβM acts on neuronal excitability of immature neurons by 
increasing the frequency and decreasing the width of APs. On the contrary, 500 nM 
AβM reduces the spiking rate and the APs width at control levels probably due to an 
ongoing oligomerization of the peptide caused by its high concentration in the culture 
medium. Besides confirming that AβM has a concentration-dependent effect on 
neurons, these results are of particular interest because they suggest that there is a 
concentration threshold under which not only AβM has a lower tendency to aggregate, 
but it also has a totally different effect than that exerted at higher concentrations. We 
think that these observations can be explained by the fact that after 72 hours in the 
culture medium, in the 10 nM preparation the predominant species of AβM are 
monomers while in the 500 nM preparation the predominant species are aggregated 
forms. Thus, depending on the proportions of the different conformations of Aβ in 
the culture medium, different effects on neuronal activity can be observed. Indeed, 
the most ambivalent AβM effects are induced by 100 nM treatment; it is perhaps due 
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to a mixed Aβ population of monomers and oligomers that leads to a balance of 
enhancing and inhibitory effects exerted by the peptide on neuronal activity (Fig.2).  
These evidences must be discussed in the light of the current results obtained from 
Aβ-overproducing transgenic mice that overexpress familial AD (FAD)-associated 
mutant APP. Most of the studies using mouse models of amiloidopathy are focused 
on the analysis of the synaptic function and plasticity. However, attention has also 
been paid on the intrinsic excitability modifications that occur in neuronal cells. The 
epileptiform electrical activity recorded in APP-overexpressing mice [123], also 
confirmed in AD sufferers [206], was the first indication of the hyperexcitability later 
identified in several mouse models of AD [127], [126], [131], [129]. The most reported 
alteration is a reduced width of APs that therefore facilitate an increase in the firing 
rate [131], [127], [129], [132]. Our results are in accordance with the literature. 
Indeed, the alterations in neuronal excitability that we report are very similar to that 
commonly observed in AD mouse models. However, with some important differences 
in the experimental conditions that allow us to interpret the results in an alternative 
fashion, attributing to Aβ-induced excitability a trophic rather than a toxic effect. In 
fact, all our experiments were performed using primary cultures of neurons at early 
stages of development (4 DIV and 7 DIV), with a highly controllable AβM preparation 
that we applied chronically on neurons.  In our opinion, the modifications induced by 
the peptide are surely dependent on its conformational form, but what we want to 
highlight as a critical issue in the study of Aβ is that every effect of the peptide can be 
toxic or trophic depending on the stage of development on the neuron.  
An Aβ-induced hyperexcitability appears to be toxic in adult brains while in juvenile 
neurons it may favor the insertion of newborn cells into neuronal network as well as 
the communication between excitable cells through synaptic activity regulation.  
Indeed, the peptide is not only produced during pathological conditions; the 
endogenous Aβ is released by APP-processing as early as the beginning of embryonic 
development and during the whole life of individuals [207]. Moreover, Brody and 
colleagues have shown that microdialysate Aβ levels in human ISF decrease almost 
immediately after an acute brain injury then increase over time until reaching a 
steady state concentration that correlates with improved neurological status [112]. 
Thus, it seems that Aβ levels increase when there is an injury in the brain, suggesting 
a fascinating hypothesis that sees Aβ as a peptide involved in brain repairing 
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processes. With this in mind, the increased excitability found in our immature 
neuronal cultures chronically exposed to AβM, would not be a toxic event but it may 
drive/help the maturation of excitable cells. Indeed the 10 nM AβM-induced APs 
narrowing resembles that displayed by neurons at more mature stages of 
development (Fig. 4). 
APs waveform is mainly controlled by the gating properties and membrane density of 
two voltage gated channels, Na+ and K+ both increasing over time during 
development [185]. In particular, the AP duration could be modified by an increase in 
the potassium currents, which contribute to the repolarization phase of AP, or an 
increase in the Na+ peak current. In our recordings, the inward sodium current was 
not affected by 10 nM AβM treatment (Fig.5), while we found a decrease in both the 
potassium currents analyzed, IKA and IKV (Fig.6). There are many studies about the 
effects induced by Aβ on potassium channels, such as IKA enhancement [208], [209], 
[210], [211] or reduction [212], [213], [132] as well as an increase in Kv3.1b delayed-
rectifier channels in a mouse model of AD [129]. However, the alterations caused by 
Aβ on potassium currents are still unclear due to the different Aβ isoforms and model 
systems used in these studies. According to our results, a decrease in IKA fits well 
with the resulting decrease in APs width found in Aβ-treated neurons; it is instead 
not easy to identify a reason for the reduction of IKV since its increase is known to be 
necessary to reduce the AP duration. This discrepancy may be probably due to the 
early stage of development at which neurons were treated and analyzed. 
The total dendritic length is enhanced by about 20% following AβM treatment at 10 
nM (Fig.8), reinforcing the idea that this concentration of AβM enhances neuronal 
maturation and affects the neuronal functioning in a positive way. Dendritic 
elongations and branching as well as synapses formation are very sensitive to 
neuronal activity [195], [214], due to its involvement in the modulation of vesicular 
release. Under developing conditions, the long-range communication between cells 
lead to a concentration gradient of glutamate neurotransmitter in the neuronal 
environment that may be detected from filopodia. The dendritic processes thus 
spread towards the pre-synapses in order to achieve an active innervation. 
Subsequently, NMDA dependent-calcium flux on the post-synapses can activate 
several intracellular pathways that subsequently lead to plasticity and synaptic 
strength [215], [216]. 
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So, electrical activity and glutamate release play an important role in dendritic 
arborization and synaptic maturation. For this reason, we decided to monitor 
spontaneous synaptic activity in immature neurons treated with 10 nM AβM to see if 
the increased dendritic length and increased electrical activity also influence synaptic 
transmission. 
Synapse strengthening was successfully measured in 7 DIV immature neurons treated 
with 10 nM AβM for 72 hours. At this stage of in vitro development, the levels of 
glutammatergic receptors (AMPA and NMDA receptors) are still increasing, as it 
happens at 4 DIV; however the synaptic markers are now detectable and many 
nascent synaptic junctions are present, while at 4 DIV it is still too early to record any 
synaptic event [217]. We then recorded the spontaneous release of excitatory 
neurotransmitters at 7 DIV after chronic treatment with 10 nM AβM and untreated 
neurons. Analysis of sEPSC showed that 10 nM AβM act at the synaptic level by 
strengthening both pre- and post-synapses. Since recordings were done using a TTX-
free external solution, sEPSC frequency and amplitude are likely augmented due to 
the strong increase in the excitability caused by the treatment (Fig. 11). The rise in 
sEPSC frequency seems to alter the post-synaptic receptor density, as demonstrated 
by the amplitude enhancement of sEPSC that can be due to an increase in the AMPA 
receptors levels at the plasma membrane. Although both frequency and amplitude 
are increased, rise and decay time of the synaptic events are unchanged meaning that 
10 nM AβM treatment does not alter the subunit composition of AMPA receptors. The 
general strengthening of synapses caused by AβM may involve the activation of newly 
formed “silent synapses” [218]: thanks to the 10 nM AβM – induced vesicle release, a 
strong postsynaptic depolarization may activate the NMDA dependent CaMKII 
pathway resulting in the appearance of a solid AMPA response in immature neurons. 
It is worthy to notice that these changes in the synaptic activity do not lead to 
excitotoxicity (Fig.12). 
By chronically blocking (72 hours) the electrical activity of the cells with TTX we 
show that the effect of AβM on synaptic activity is almost zeroed, demonstrating that 
the augmented spiking activity of 10 nM AβM-treated neurons is fundamental for the 
strengthening of synapses (Fig.13). Moreover, by blocking the electrical activity with 
TTX for 72 hours, we show that the dendritic arbor spreading no longer occurs in 
neurons treated with AβM, thus demonstrating that also the dendritic length is 
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dependent from the enhanced neuronal activity that occurs in AβM -treated neurons 
(Fig.14).  
The constant rise of AMPA receptors during early stages of neuronal development is 
strictly dependent on NMDA receptors activity [196], which quantal size is stable 
during synaptogenesis [219].  Thus, when an increase in the AMPA signal is needed, 
an NMDA activity-deprivation may cause a compensatory reaction of cells that over-
produce AMPA receptors. Indeed the chronic block (72 hours) of NMDA receptors 
(with APV or high Mg2+) correlates with an increased AMPA response, as shown by 
the increase of both sEPSC frequency and amplitude recorded from Aβ-untreated 
neurons. However, sEPSC frequency of neurons cultured with both 10 nM AβM and 
APV (or high Mg2+) drastically decreases at control values whereas the amplitude 
remains unchanged from APV-control neurons (Fig.16A, B). This is an intriguing 
result in light of the reported Aβ function as a Ca2+ like ion channel. It has been 
reported that Aβ peptides induce ionic conductances in both artificial membranes 
and plasma membranes [220], [221]–[223], [224]. Unpublished data obtained from 
our laboratory also confirmed this idea revealing pore formation in artificial 
membrane when exposed to AβM at 100 nM. Current recordings in artificial lipid 
bilayer showed that Aβ, in its monomeric form, not only is able to form ion pores with 
low conductance (15-20 pS) but also that this ion flux is mainly calcium and 
potassium selective. We speculate that the tiny calcium flux mediated by monomeric 
Aβ channels is able to recover the effects obtained during NMDA activity-deprived 
conditions. As described by Nicoll’s group [225], the strength of developing synapses 
is modulated by the magnitude of NMDA receptors activation. That is, the basal 
NMDA activity seems to have an inhibitory role on AMPA receptors membrane 
insertion in developing conditions. This inhibitory pathway may ensure that synapses 
become functional only after strong activity, which instead triggers AMPA receptors 
insertion because of the sustained intracellular calcium flux mediated by NMDA 
receptors in this condition. Eliminating NMDA receptors during development, the 
inhibitory modulation of the synaptic strength is also abolished, leading to an 
increase in the active AMPA receptors on post-synaptic membranes [225]. Thus, 
when NMDA receptors are blocked with APV or high Mg2+, Aβ-mediated calcium flux 
seems to override the NMDA current. When neurons are exposed to both APV and 
AβM the sEPSC amplitude remains unchanged, meaning that the calcium currents 
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mediated by AβM may mimic the current mediated by NMDA receptors when 
synapses are hyper-stimulated.  
In light of this, post-synaptic strengthening induced by the monomeric peptide may 
trigger a retrograde pathway that reduces the probability of vesicular release, thus the 
sEPSC frequency, as observed in our sEPSC recordings (Fig. 16A). In summary, Aβ 
might act on synapses by mediating a calcium flux that mimics or enhances NMDA 
receptors role in synaptogenesis and by increasing the electrical activity of neurons.  
It has been demonstrated that the release of the native peptide in the brain ISF is 
regulated by neuronal activity [161], [160]. Although the physiological concentrations 
of the peptide is reported to be lower than 10 nM, monomeric Aβ levels probably 
fluctuate into the neuronal network within a range of nano-to-picomolar 
concentrations in which the peptide may exert different effects on neuronal cells. 
Indeed, it has been already suggested a mechanism by which Aβ and the synaptic 
activity are mutually controlled: picomolar concentrations of Aβ, like physiological, 
enhance LTP and memory [164]. The resulting increase in the synaptic activity 
increases in turn the peptide concentrations leading to the formation of oligomers 
responsible for the synaptic activity depression. Our evidences suggest a modulatory 
role of monomeric Aβ on both electrical and synaptic activity of immature cortical 
neurons, probably through partially overlapping mechanisms. Although the cell 
viability is not affected by the exposure to increasing amounts of monomers (10 nM, 
100 nM, 500 nM), only 10 nM AβM positively alter the activity of juvenile neurons. As 
shown, the AβM-induced firing activity increase is fundamental to drive the growth of 
the dendritic arbor and also the strengthening of synapses in developing neurons. 
Moreover, monomeric Aβ, as calcium like channel, could be involved in the 
stimulation of several processes involved in the maturation of a neuron. It has been 
already described a trophic function of Aβ on both proliferation and differentiation of 
neuronal stem cells (NSC) but the precise effect is still unknown due to the 
contradictory results so far obtained [173]. The overall evidences described in my 
thesis work suggest that the AβM-dependent modulation of immature neuronal 
activity might be crucial for the insertion of newborn neurons into a pre-existing 
network.  
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In conclusion, this work wants to give an input to reassess the physiological role of Aβ 
that must be considered to further develop most efficient therapeutic interventions 
for AD. 
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